ID   CFTR_HUMAN              Reviewed;        1480 AA.
AC   P13569; Q20BG8; Q20BH2; Q2I0A1; Q2I102;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   15-MAY-2007, sequence version 3.
DT   10-MAY-2017, entry version 226.
DE   RecName: Full=Cystic fibrosis transmembrane conductance regulator;
DE            Short=CFTR;
DE   AltName: Full=ATP-binding cassette sub-family C member 7;
DE   AltName: Full=Channel conductance-controlling ATPase;
DE            EC=3.6.3.49 {ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:15284228, ECO:0000269|PubMed:26627831, ECO:0000269|PubMed:8910473};
DE   AltName: Full=cAMP-dependent chloride channel;
GN   Name=CFTR; Synonyms=ABCC7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-470.
RX   PubMed=2475911; DOI=10.1126/science.2475911;
RA   Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R.,
RA   Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J.-L.,
RA   Drumm M.L., Iannuzzi M.C., Collins F.S., Tsui L.-C.;
RT   "Identification of the cystic fibrosis gene: cloning and
RT   characterization of complementary DNA.";
RL   Science 245:1066-1073(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-470.
RX   PubMed=1710598; DOI=10.1016/0888-7543(91)90503-7;
RA   Zielenski J., Rozmahel R., Bozon D., Kerem B., Grzelczak Z.,
RA   Riordan J.R., Rommens J., Tsui L.-C.;
RT   "Genomic DNA sequence of the cystic fibrosis transmembrane conductance
RT   regulator (CFTR) gene.";
RL   Genomics 10:214-228(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-470 AND TRP-1453.
RA   Stacy R., Subramanian S., Deodato C., Burkhardt P., Song Y.,
RA   Paddock M., Chang J., Zhou Y., Haugen E., Waring D., Chapman P.,
RA   Hayden H., Levy R., Wu Z., Rouse G., James R., Phelps K., Olson M.V.,
RA   Kaul R.;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   PHOSPHORYLATION AT SER-660; SER-686; SER-700; SER-737; SER-768;
RP   SER-790; SER-795 AND SER-813.
RX   PubMed=1377674;
RA   Picciotto M.R., Cohn J.A., Bertuzzi G., Greenguard P., Nairn A.C.;
RT   "Phosphorylation of the cystic fibrosis transmembrane conductance
RT   regulator.";
RL   J. Biol. Chem. 267:12742-12752(1992).
RN   [7]
RP   GLYCOSYLATION AT ASN-894 AND ASN-900, AND TOPOLOGY.
RX   PubMed=7518437;
RA   Chang X.-B., Hou Y.-X., Jensen T.J., Riordan J.R.;
RT   "Mapping of cystic fibrosis transmembrane conductance regulator
RT   membrane topology by glycosylation site insertion.";
RL   J. Biol. Chem. 269:18572-18575(1994).
RN   [8]
RP   PHOSPHORYLATION AT SER-660; SER-700; SER-712; SER-737; SER-753;
RP   SER-768; SER-795 AND SER-813.
RX   PubMed=9385646; DOI=10.1002/pro.5560061117;
RA   Neville D.C.A., Rozanas C.R., Rice E.M., Gruis D.B., Verkman A.S.,
RA   Townsend R.R.;
RT   "Evidence for phosphorylation of serine 753 in CFTR using a novel
RT   metal-ion affinity resin and matrix-assisted laser desorption mass
RT   spectrometry.";
RL   Protein Sci. 6:2436-2445(1997).
RN   [9]
RP   ALTERNATIVE SPLICING (ISOFORM 2).
RX   PubMed=10766763; DOI=10.1074/jbc.M910165199;
RA   Pagani F., Buratti E., Stuani C., Romano M., Zuccato E., Niksic M.,
RA   Giglio L., Faraguna D., Baralle F.E.;
RT   "Splicing factors induce cystic fibrosis transmembrane regulator exon
RT   9 skipping through a nonevolutionary conserved intronic element.";
RL   J. Biol. Chem. 275:21041-21047(2000).
RN   [10]
RP   DOMAIN, FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=10792060; DOI=10.1073/pnas.100588797;
RA   Ostedgaard L.S., Baldursson O., Vermeer D.W., Welsh M.J.,
RA   Robertson A.D.;
RT   "A functional R domain from cystic fibrosis transmembrane conductance
RT   regulator is predominantly unstructured in solution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5657-5662(2000).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=11524016; DOI=10.1021/bi0108195;
RA   Ramjeesingh M., Li C., Kogan I., Wang Y., Huan L.J., Bear C.E.;
RT   "A monomer is the minimum functional unit required for channel and
RT   ATPase activity of the cystic fibrosis transmembrane conductance
RT   regulator.";
RL   Biochemistry 40:10700-10706(2001).
RN   [12]
RP   INTERACTION WITH GOPC, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11707463; DOI=10.1074/jbc.M110177200;
RA   Cheng J., Moyer B.D., Milewski M., Loffing J., Ikeda M., Mickle J.E.,
RA   Cutting G.R., Li M., Stanton B.A., Guggino W.B.;
RT   "A Golgi-associated PDZ domain protein modulates cystic fibrosis
RT   transmembrane regulator plasma membrane expression.";
RL   J. Biol. Chem. 277:3520-3529(2002).
RN   [13]
RP   INTERACTION WITH SLC4A7 AND SLC9A3R1, AND FUNCTION.
RX   PubMed=12403779; DOI=10.1074/jbc.M201862200;
RA   Park M., Ko S.B.H., Choi J.Y., Muallem G., Thomas P.J., Pushkin A.,
RA   Lee M.-S., Kim J.Y., Lee M.G., Muallem S., Kurtz I.;
RT   "The cystic fibrosis transmembrane conductance regulator interacts
RT   with and regulates the activity of the HCO3- salvage transporter human
RT   Na+-HCO3-cotransport isoform 3.";
RL   J. Biol. Chem. 277:50503-50509(2002).
RN   [14]
RP   PHOSPHORYLATION BY AMPK, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12519745; DOI=10.1152/ajpcell.00227.2002;
RA   Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.;
RT   "Physiological modulation of CFTR activity by AMP-activated protein
RT   kinase in polarized T84 cells.";
RL   Am. J. Physiol. 284:C1297-C1308(2003).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15010471; DOI=10.1074/jbc.M313323200;
RA   Shcheynikov N., Kim K.H., Kim K.M., Dorwart M.R., Ko S.B., Goto H.,
RA   Naruse S., Thomas P.J., Muallem S.;
RT   "Dynamic control of cystic fibrosis transmembrane conductance
RT   regulator Cl(-)/HCO3(-) selectivity by external Cl(-).";
RL   J. Biol. Chem. 279:21857-21865(2004).
RN   [16]
RP   INTERACTION WITH MYO6, AND SUBCELLULAR LOCATION.
RX   PubMed=15247260; DOI=10.1074/jbc.M403141200;
RA   Swiatecka-Urban A., Boyd C., Coutermarsh B., Karlson K.H., Barnaby R.,
RA   Aschenbrenner L., Langford G.M., Hasson T., Stanton B.A.;
RT   "Myosin VI regulates endocytosis of the cystic fibrosis transmembrane
RT   conductance regulator.";
RL   J. Biol. Chem. 279:38025-38031(2004).
RN   [17]
RP   REVIEW.
RX   PubMed=1378801;
RA   McIntosh I., Cutting G.R.;
RT   "Cystic fibrosis transmembrane conductance regulator and the etiology
RT   and pathogenesis of cystic fibrosis.";
RL   FASEB J. 6:2775-2782(1992).
RN   [18]
RP   ALTERNATIVE SPLICING (ISOFORM 3).
RX   PubMed=12913074; DOI=10.1093/hmg/ddg215;
RA   Aznarez I., Chan E.M., Zielenski J., Blencowe B.J., Tsui L.-C.;
RT   "Characterization of disease-associated mutations affecting an exonic
RT   splicing enhancer and two cryptic splice sites in exon 13 of the
RT   cystic fibrosis transmembrane conductance regulator gene.";
RL   Hum. Mol. Genet. 12:2031-2040(2003).
RN   [19]
RP   CHANNEL GATING REGULATION, PHOSPHORYLATION, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12588899; DOI=10.1113/jphysiol.2002.035790;
RA   Chappe V., Hinkson D.A., Zhu T., Chang X.B., Riordan J.R.,
RA   Hanrahan J.W.;
RT   "Phosphorylation of protein kinase C sites in NBD1 and the R domain
RT   control CFTR channel activation by PKA.";
RL   J. Physiol. (Lond.) 548:39-52(2003).
RN   [20]
RP   FUNCTION.
RX   PubMed=14668433; DOI=10.1073/pnas.2634339100;
RA   Coakley R.D., Grubb B.R., Paradiso A.M., Gatzy J.T., Johnson L.G.,
RA   Kreda S.M., O'Neal W.K., Boucher R.C.;
RT   "Abnormal surface liquid pH regulation by cultured cystic fibrosis
RT   bronchial epithelium.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:16083-16088(2003).
RN   [21]
RP   CATALYTIC ACTIVITY, AND DOMAIN.
RX   PubMed=15284228; DOI=10.1074/jbc.M407666200;
RA   Kidd J.F., Ramjeesingh M., Stratford F., Huan L.J., Bear C.E.;
RT   "A heteromeric complex of the two nucleotide binding domains of cystic
RT   fibrosis transmembrane conductance regulator (CFTR) mediates ATPase
RT   activity.";
RL   J. Biol. Chem. 279:41664-41669(2004).
RN   [22]
RP   FUNCTION.
RX   PubMed=16645176; DOI=10.1164/rccm.200506-987OC;
RA   Blouquit S., Regnier A., Dannhoffer L., Fermanian C., Naline E.,
RA   Boucher R., Chinet T.;
RT   "Ion and fluid transport properties of small airways in cystic
RT   fibrosis.";
RL   Am. J. Respir. Crit. Care Med. 174:299-305(2006).
RN   [23]
RP   DOMAIN, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17036051; DOI=10.1038/sj.emboj.7601373;
RA   Mense M., Vergani P., White D.M., Altberg G., Nairn A.C., Gadsby D.C.;
RT   "In vivo phosphorylation of CFTR promotes formation of a nucleotide-
RT   binding domain heterodimer.";
RL   EMBO J. 25:4728-4739(2006).
RN   [24]
RP   IDENTIFICATION IN A COMPLEX WITH RAB11A AND MYO5B, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17462998; DOI=10.1074/jbc.M608531200;
RA   Swiatecka-Urban A., Talebian L., Kanno E., Moreau-Marquis S.,
RA   Coutermarsh B., Hansen K., Karlson K.H., Barnaby R., Cheney R.E.,
RA   Langford G.M., Fukuda M., Stanton B.A.;
RT   "Myosin Vb is required for trafficking of the cystic fibrosis
RT   transmembrane conductance regulator in Rab11a-specific apical
RT   recycling endosomes in polarized human airway epithelial cells.";
RL   J. Biol. Chem. 282:23725-23736(2007).
RN   [25]
RP   FUNCTION.
RX   PubMed=17434346; DOI=10.1016/j.jcf.2007.03.001;
RA   Lu C., Jiang C., Pribanic S., Rotin D.;
RT   "CFTR stabilizes ENaC at the plasma membrane.";
RL   J. Cyst. Fibros. 6:419-422(2007).
RN   [26]
RP   DOMAIN.
RX   PubMed=17660831; DOI=10.1038/nsmb1278;
RA   Baker J.M., Hudson R.P., Kanelis V., Choy W.Y., Thibodeau P.H.,
RA   Thomas P.J., Forman-Kay J.D.;
RT   "CFTR regulatory region interacts with NBD1 predominantly via multiple
RT   transient helices.";
RL   Nat. Struct. Mol. Biol. 14:738-745(2007).
RN   [27]
RP   UBIQUITINATION, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=19398555; DOI=10.1074/jbc.M109.001685;
RA   Bomberger J.M., Barnaby R.L., Stanton B.A.;
RT   "The deubiquitinating enzyme USP10 regulates the post-endocytic
RT   sorting of cystic fibrosis transmembrane conductance regulator in
RT   airway epithelial cells.";
RL   J. Biol. Chem. 284:18778-18789(2009).
RN   [28]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19019741; DOI=10.1016/j.jcf.2008.10.004;
RA   Tang L., Fatehi M., Linsdell P.;
RT   "Mechanism of direct bicarbonate transport by the CFTR anion
RT   channel.";
RL   J. Cyst. Fibros. 8:115-121(2009).
RN   [29]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19621064; DOI=10.1371/journal.pbio.1000155;
RA   Zhang L., Button B., Gabriel S.E., Burkett S., Yan Y.,
RA   Skiadopoulos M.H., Dang Y.L., Vogel L.N., McKay T., Mengos A.,
RA   Boucher R.C., Collins P.L., Pickles R.J.;
RT   "CFTR delivery to 25% of surface epithelial cells restores normal
RT   rates of mucus transport to human cystic fibrosis airway epithelium.";
RL   PLoS Biol. 7:E1000155-E1000155(2009).
RN   [30]
RP   INTERACTION WITH CSE1L.
RX   PubMed=20933420; DOI=10.1016/j.cub.2010.09.012;
RA   Bagnat M., Navis A., Herbstreith S., Brand-Arzamendi K., Curado S.,
RA   Gabriel S., Mostov K., Huisken J., Stainier D.Y.;
RT   "Cse1l is a negative regulator of CFTR-dependent fluid secretion.";
RL   Curr. Biol. 20:1840-1845(2010).
RN   [31]
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT CF PHE-508 DEL,
RP   MUTAGENESIS OF ASN-894 AND ASN-900, AND GLYCOSYLATION AT ASN-894 AND
RP   ASN-900.
RX   PubMed=20008117; DOI=10.1152/ajplung.00016.2009;
RA   Cholon D.M., O'Neal W.K., Randell S.H., Riordan J.R., Gentzsch M.;
RT   "Modulation of endocytic trafficking and apical stability of CFTR in
RT   primary human airway epithelial cultures.";
RL   Am. J. Physiol. 298:L304-L314(2010).
RN   [32]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=19923167; DOI=10.1093/humrep/dep406;
RA   Li C.Y., Jiang L.Y., Chen W.Y., Li K., Sheng H.Q., Ni Y., Lu J.X.,
RA   Xu W.X., Zhang S.Y., Shi Q.X.;
RT   "CFTR is essential for sperm fertilizing capacity and is correlated
RT   with sperm quality in humans.";
RL   Hum. Reprod. 25:317-327(2010).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-549, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [34]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ANO1.
RX   PubMed=22178883; DOI=10.1159/000335765;
RA   Ousingsawat J., Kongsuphol P., Schreiber R., Kunzelmann K.;
RT   "CFTR and TMEM16A are separate but functionally related Cl-channels.";
RL   Cell. Physiol. Biochem. 28:715-724(2011).
RN   [35]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=22207244; DOI=10.1007/s00418-011-0904-1;
RA   Enuka Y., Hanukoglu I., Edelheit O., Vaknine H., Hanukoglu A.;
RT   "Epithelial sodium channels (ENaC) are uniformly distributed on motile
RT   cilia in the oviduct and the respiratory airways.";
RL   Histochem. Cell Biol. 137:339-353(2012).
RN   [36]
RP   INTERACTION WITH SLC26A8.
RX   PubMed=22121115; DOI=10.1093/hmg/ddr558;
RA   Rode B., Dirami T., Bakouh N., Rizk-Rabin M., Norez C., Lhuillier P.,
RA   Lores P., Jollivet M., Melin P., Zvetkova I., Bienvenu T., Becq F.,
RA   Planelles G., Edelman A., Gacon G., Toure A.;
RT   "The testis anion transporter TAT1 (SLC26A8) physically and
RT   functionally interacts with the cystic fibrosis transmembrane
RT   conductance regulator channel: a potential role during sperm
RT   capacitation.";
RL   Hum. Mol. Genet. 21:1287-1298(2012).
RN   [37]
RP   PHOSPHORYLATION AT SER-660; SER-686; SER-700; SER-712; THR-717;
RP   SER-737; SER-795; SER-1444 AND SER-1456, UBIQUITINATION AT LYS-688,
RP   PALMITOYLATION AT CYS-524 AND CYS-1395, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=22119790; DOI=10.1093/protein/gzr054;
RA   McClure M., Delucas L.J., Wilson L., Ray M., Rowe S.M., Wu X., Dai Q.,
RA   Hong J.S., Sorscher E.J., Kappes J.C., Barnes S.;
RT   "Purification of CFTR for mass spectrometry analysis: identification
RT   of palmitoylation and other post-translational modifications.";
RL   Protein Eng. Des. Sel. 25:7-14(2012).
RN   [38]
RP   UBIQUITINATION BY RNF185.
RX   PubMed=24019521; DOI=10.1074/jbc.M113.470500;
RA   El Khouri E., Le Pavec G., Toledano M.B., Delaunay-Moisan A.;
RT   "RNF185 is a novel E3 ligase of endoplasmic reticulum-associated
RT   degradation (ERAD) that targets cystic fibrosis transmembrane
RT   conductance regulator (CFTR).";
RL   J. Biol. Chem. 288:31177-31191(2013).
RN   [39]
RP   FUNCTION, CHARACTERIZATION OF CF VARIANT PHE-508 DEL, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION AT SER-660; SER-670; SER-700; SER-712;
RP   SER-737; SER-753; SER-768; SER-795 AND SER-813, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=25330774; DOI=10.1002/pmic.201400218;
RA   Pasyk S., Molinski S., Ahmadi S., Ramjeesingh M., Huan L.J., Chin S.,
RA   Du K., Yeger H., Taylor P., Moran M.F., Bear C.E.;
RT   "The major cystic fibrosis causing mutation exhibits defective
RT   propensity for phosphorylation.";
RL   Proteomics 15:447-461(2015).
RN   [40]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=26627831; DOI=10.1074/jbc.M115.704809;
RA   Ehrhardt A., Chung W.J., Pyle L.C., Wang W., Nowotarski K.,
RA   Mulvihill C.M., Ramjeesingh M., Hong J., Velu S.E., Lewis H.A.,
RA   Atwell S., Aller S., Bear C.E., Lukacs G.L., Kirk K.L., Sorscher E.J.;
RT   "Channel gating regulation by the cystic fibrosis transmembrane
RT   conductance regulator (CFTR) first cytosolic loop.";
RL   J. Biol. Chem. 291:1854-1865(2016).
RN   [41]
RP   FUNCTION.
RX   PubMed=26823428; DOI=10.1126/science.aad5589;
RA   Shah V.S., Meyerholz D.K., Tang X.X., Reznikov L., Abou Alaiwa M.,
RA   Ernst S.E., Karp P.H., Wohlford-Lenane C.L., Heilmann K.P.,
RA   Leidinger M.R., Allen P.D., Zabner J., McCray P.B. Jr.,
RA   Ostedgaard L.S., Stoltz D.A., Randak C.O., Welsh M.J.;
RT   "Airway acidification initiates host defense abnormalities in cystic
RT   fibrosis mice.";
RL   Science 351:503-507(2016).
RN   [42]
RP   FUNCTION.
RX   PubMed=27941075; DOI=10.1152/ajplung.00375.2016;
RA   Rauh R., Hoerner C., Korbmacher C.;
RT   "deltabetagamma-ENaC is inhibited by CFTR but stimulated by cAMP in
RT   Xenopus laevis oocytes.";
RL   Am. J. Physiol. 312:L277-L287(2017).
RN   [43]
RP   FUNCTION.
RX   PubMed=27714810; DOI=10.1002/jcp.25634;
RA   Puga Molina L.C., Pinto N.A., Torres Rodriguez P., Romarowski A.,
RA   Vicens Sanchez A., Visconti P.E., Darszon A., Trevino C.L.,
RA   Buffone M.G.;
RT   "Essential role of CFTR in PKA-dependent phosphorylation,
RT   alkalinization, and hyperpolarization during human sperm
RT   capacitation.";
RL   J. Cell. Physiol. 232:1404-1414(2017).
RN   [44]
RP   3D-STRUCTURE MODELING OF 425-638.
RX   PubMed=9517543;
RX   DOI=10.1002/(SICI)1097-0134(19980215)30:3<275::AID-PROT7>3.3.CO;2-L;
RA   Hoedemaeker F.J., Davidson A.R., Rose D.R.;
RT   "A model for the nucleotide-binding domains of ABC transporters based
RT   on the large domain of aspartate aminotransferase.";
RL   Proteins 30:275-286(1998).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1476-1480 IN COMPLEX WITH
RP   SLC9A3R1.
RX   PubMed=11304524; DOI=10.1074/jbc.C100154200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural basis of the Na+/H+ exchanger regulatory factor PDZ1
RT   interaction with the carboxyl-terminal region of the cystic fibrosis
RT   transmembrane conductance regulator.";
RL   J. Biol. Chem. 276:19683-19686(2001).
RN   [46] {ECO:0000244|PDB:2LOB}
RP   STRUCTURE BY NMR OF 1473-1480 IN COMPLEX WITH GOPC.
RX   PubMed=16331976; DOI=10.1021/bi0516475;
RA   Piserchio A., Fellows A., Madden D.R., Mierke D.F.;
RT   "Association of the cystic fibrosis transmembrane regulator with CAL:
RT   structural features and molecular dynamics.";
RL   Biochemistry 44:16158-16166(2005).
RN   [47] {ECO:0000244|PDB:1XMI, ECO:0000244|PDB:1XMJ}
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 389-678 OF WILD-TYPE AND
RP   VARIANT CF PHE-508 DEL IN COMPLEX WITH ATP, AND CHARACTERIZATION OF
RP   VARIANT CF PHE-508 DEL.
RX   PubMed=15528182; DOI=10.1074/jbc.M410968200;
RA   Lewis H.A., Zhao X., Wang C., Sauder J.M., Rooney I., Noland B.W.,
RA   Lorimer D., Kearins M.C., Conners K., Condon B., Maloney P.C.,
RA   Guggino W.B., Hunt J.F., Emtage S.;
RT   "Impact of the deltaF508 mutation in first nucleotide-binding domain
RT   of human cystic fibrosis transmembrane conductance regulator on domain
RT   folding and structure.";
RL   J. Biol. Chem. 280:1346-1353(2005).
RN   [48] {ECO:0000244|PDB:3GD7}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 1193-1435 AND 1458-1470 IN
RP   COMPLEX WITH ATP ANALOG.
RA   Atwell S., Antonysamy S., Guggino W.B., Conners K., Emtage S.,
RA   Gheyi T., Hunt J.F., Lewis H.A., Lu F., Sauder J.M., Weber P.C.,
RA   Wetmore D., Zhao X.;
RT   "Crystal structure of human NBD2 complexed with N6-phenylethyl-ATP (P-
RT   ATP).";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [49] {ECO:0000244|PDB:2BBO, ECO:0000244|PDB:2BBS, ECO:0000244|PDB:2BBT}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 389-677 IN COMPLEX WITH ATP.
RX   PubMed=19944699; DOI=10.1016/j.jmb.2009.11.051;
RA   Lewis H.A., Wang C., Zhao X., Hamuro Y., Conners K., Kearins M.C.,
RA   Lu F., Sauder J.M., Molnar K.S., Coales S.J., Maloney P.C.,
RA   Guggino W.B., Wetmore D.R., Weber P.C., Hunt J.F.;
RT   "Structure and dynamics of NBD1 from CFTR characterized using
RT   crystallography and hydrogen/deuterium exchange mass spectrometry.";
RL   J. Mol. Biol. 396:406-430(2010).
RN   [50] {ECO:0000244|PDB:2PZE, ECO:0000244|PDB:2PZF, ECO:0000244|PDB:2PZG}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 387-646 IN COMPLEX WITH ATP,
RP   AND CHARACTERIZATION OF VARIANT CF PHE-508 DEL.
RX   PubMed=20150177; DOI=10.1093/protein/gzq004;
RA   Atwell S., Brouillette C.G., Conners K., Emtage S., Gheyi T.,
RA   Guggino W.B., Hendle J., Hunt J.F., Lewis H.A., Lu F.,
RA   Protasevich I.I., Rodgers L.A., Romero R., Wasserman S.R., Weber P.C.,
RA   Wetmore D., Zhang F.F., Zhao X.;
RT   "Structures of a minimal human CFTR first nucleotide-binding domain as
RT   a monomer, head-to-tail homodimer, and pathogenic mutant.";
RL   Protein Eng. Des. Sel. 23:375-384(2010).
RN   [51]
RP   STRUCTURE BY ELECTRON MICROSCOPY (9 ANGSTROMS).
RX   PubMed=21931164; DOI=10.1074/jbc.M111.292268;
RA   Rosenberg M.F., O'Ryan L.P., Hughes G., Zhao Z., Aleksandrov L.A.,
RA   Riordan J.R., Ford R.C.;
RT   "The cystic fibrosis transmembrane conductance regulator (CFTR):
RT   three-dimensional structure and localization of a channel gate.";
RL   J. Biol. Chem. 286:42647-42654(2011).
RN   [52] {ECO:0000244|PDB:4WZ6}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 389-678.
RX   PubMed=26444971; DOI=10.1002/pro.2821;
RA   Hall J.D., Wang H., Byrnes L.J., Shanker S., Wang K., Efremov I.V.,
RA   Chong P.A., Forman-Kay J.D., Aulabaugh A.E.;
RT   "Binding screen for cystic fibrosis transmembrane conductance
RT   regulator correctors finds new chemical matter and yields insights
RT   into cystic fibrosis therapeutic strategy.";
RL   Protein Sci. 25:360-373(2016).
RN   [53] {ECO:0000244|PDB:5UAK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.87 ANGSTROMS), AND TOPOLOGY.
RA   Liu F., Zhang Z., Chen J.;
RT   "Structure of human cystic fibrosis transmembrane conductance
RT   regulator (CFTR).";
RL   Submitted (DEC-2016) to the PDB data bank.
RN   [54]
RP   REVIEW ON VARIANTS.
RX   PubMed=1284534; DOI=10.1002/humu.1380010304;
RA   Tsui L.-C.;
RT   "Mutations and sequence variations detected in the cystic fibrosis
RT   transmembrane conductance regulator (CFTR) gene: a report from the
RT   Cystic Fibrosis Genetic Analysis Consortium.";
RL   Hum. Mutat. 1:197-203(1992).
RN   [55]
RP   CHARACTERIZATION OF VARIANT CF TRP-334; ILE-507 DEL; PHE-508 DEL;
RP   ASP-551 AND ILE-549, MUTAGENESIS OF LYS-464; PHE-508 AND LYS-1250, AND
RP   GLYCOSYLATION.
RX   PubMed=1699669; DOI=10.1016/0092-8674(90)90148-8;
RA   Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W.,
RA   White G.A., O'Riordan C.R., Smith A.E.;
RT   "Defective intracellular transport and processing of CFTR is the
RT   molecular basis of most cystic fibrosis.";
RL   Cell 63:827-834(1990).
RN   [56]
RP   VARIANTS CF.
RX   PubMed=1695717; DOI=10.1038/346366a0;
RA   Cutting G.R., Kasch L.M., Rosenstein B.J., Zielenski J., Tsui L.-C.,
RA   Antonarakis S.E., Kazazian H.H. Jr.;
RT   "A cluster of cystic fibrosis mutations in the first nucleotide-
RT   binding fold of the cystic fibrosis conductance regulator protein.";
RL   Nature 346:366-369(1990).
RN   [57]
RP   VARIANTS CF.
RX   PubMed=2236053; DOI=10.1073/pnas.87.21.8447;
RA   Kerem B.-S., Zielenski J., Markiewicz D., Bozon D., Gazit E.,
RA   Yahav J., Kennedy D., Riordan J.R., Collins F.S., Rommens J.M.,
RA   Tsui L.-C.;
RT   "Identification of mutations in regions corresponding to the two
RT   putative nucleotide (ATP)-binding folds of the cystic fibrosis gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8447-8451(1990).
RN   [58]
RP   VARIANTS CF.
RX   PubMed=1710600; DOI=10.1016/0888-7543(91)90510-L;
RA   White M.B., Krueger L.J., Holsclaw D.S. Jr., Gerrard B.C., Stewart C.,
RA   Quittell L., Dolganov G., Baranov V., Ivaschenko T., Kapronov N.I.,
RA   Sebastio G., Castiglione O., Dean M.;
RT   "Detection of three rare frameshift mutations in the cystic fibrosis
RT   gene in an African-American (CF444delA), an Italian (CF2522insC), and
RT   a Soviet (CF3821delT).";
RL   Genomics 10:266-269(1991).
RN   [59]
RP   CHARACTERIZATION OF CF VARIANTS ILE-507 DEL; PHE-508 DEL; ILE-549;
RP   ARG-549; ASP-551; THR-559; ASN-572; LYS-1303 AND ASP-1349, FUNCTION,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-508.
RX   PubMed=1712898; DOI=10.1128/MCB.11.8.3886;
RA   Gregory R.J., Rich D.P., Cheng S.H., Souza D.W., Paul S.,
RA   Manavalan P., Anderson M.P., Welsh M.J., Smith A.E.;
RT   "Maturation and function of cystic fibrosis transmembrane conductance
RT   regulator variants bearing mutations in putative nucleotide-binding
RT   domains 1 and 2.";
RL   Mol. Cell. Biol. 11:3886-3893(1991).
RN   [60]
RP   VARIANTS CF PHE-520 AND HIS-1291.
RX   PubMed=1284466; DOI=10.1093/hmg/1.1.11;
RA   Jones C.T., McIntosh I., Keston M., Ferguson A., Brock D.J.H.;
RT   "Three novel mutations in the cystic fibrosis gene detected by
RT   chemical cleavage: analysis of variant splicing and a nonsense
RT   mutation.";
RL   Hum. Mol. Genet. 1:11-17(1992).
RN   [61]
RP   VARIANT CF MET-1283.
RX   PubMed=1284468; DOI=10.1093/hmg/1.2.123;
RA   Cheadle J.P., Meredith A.L., Al-Jader L.N.;
RT   "A new missense mutation (R1283M) in exon 20 of the cystic fibrosis
RT   transmembrane conductance regulator gene.";
RL   Hum. Mol. Genet. 1:123-125(1992).
RN   [62]
RP   VARIANT CF PRO-1255.
RX   PubMed=1284530; DOI=10.1093/hmg/1.6.441;
RA   Lissens W., Bonduelle M., Malfroot A., Dab I., Liebaers I.;
RT   "A serine to proline substitution (S1255P) in the second nucleotide
RT   binding fold of the cystic fibrosis gene.";
RL   Hum. Mol. Genet. 1:441-442(1992).
RN   [63]
RP   VARIANTS CF LYS-92 AND CYS-117.
RX   PubMed=1284529; DOI=10.1093/hmg/1.6.439;
RA   Shackleton S., Beards F., Harris A.;
RT   "Detection of novel and rare mutations in exon 4 of the cystic
RT   fibrosis gene by SSCP.";
RL   Hum. Mol. Genet. 1:439-440(1992).
RN   [64]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL AND ASP-551, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=1284548; DOI=10.1038/ng0892-321;
RA   Kartner N., Augustinas O., Jensen T.J., Naismith A.L., Riordan J.R.;
RT   "Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland.";
RL   Nat. Genet. 1:321-327(1992).
RN   [65]
RP   VARIANT CF LYS-1101.
RX   PubMed=7680525;
RA   Zielenski J., Fugiwara T.M., Markiewicz D., Paradis A.J.,
RA   Anacleto A.I., Richards B., Schwartz R.H., Klinger K.W., Tsui L.-C.,
RA   Morgan K.;
RT   "Identification of the M1101K mutation in the cystic fibrosis
RT   transmembrane conductance regulator (CFTR) gene and complete detection
RT   of cystic fibrosis mutations in the Hutterite population.";
RL   Am. J. Hum. Genet. 52:609-615(1993).
RN   [66]
RP   VARIANTS CF VAL-1052; ARG-1061; LEU-1066; GLN-1070; ARG-1085 AND
RP   ARG-1101.
RX   PubMed=7683628; DOI=10.1006/geno.1993.1183;
RA   Mercier B., Lissens W., Novelli G., Kalaydjieva L., De Arce M.,
RA   Kapranov N., Klain N.C., Lenoir G., Chauveau P., Lenaerts C.,
RA   Rault G., Cashman S., Sangiuolo F., Audrezet M.-P., Dallapiccola B.,
RA   Guillermit H., Bonduelle M., Liebaers I., Quere I., Verlingue C.,
RA   Ferec C.;
RT   "Identification of eight novel mutations in a collaborative analysis
RT   of a part of the second transmembrane domain of the CFTR gene.";
RL   Genomics 16:296-297(1993).
RN   [67]
RP   VARIANT CF LYS-92.
RX   PubMed=7683954; DOI=10.1093/hmg/2.1.79;
RA   Nunes V., Chillon M., Doerk T., Tuemmler B., Casals T., Estivill X.;
RT   "A new missense mutation (E92K) in the first transmembrane domain of
RT   the CFTR gene causes a benign cystic fibrosis phenotype.";
RL   Hum. Mol. Genet. 2:79-80(1993).
RN   [68]
RP   VARIANT CF SER-205.
RX   PubMed=7505694; DOI=10.1093/hmg/2.10.1741;
RA   Chillon M., Casals T., Nunes V., Gimenez J., Ruiz E.P., Estivill X.;
RT   "Identification of a new missense mutation (P205S) in the first
RT   transmembrane domain of the CFTR gene associated with a mild cystic
RT   fibrosis phenotype.";
RL   Hum. Mol. Genet. 2:1741-1742(1993).
RN   [69]
RP   VARIANTS CF.
RX   PubMed=7504969; DOI=10.1002/humu.1380020511;
RA   Gasparini P., Marigo C., Bisceglia G., Nicolis E., Zelante L.,
RA   Bombieri C., Borgo G., Pignatti P.F., Cabrini G.;
RT   "Screening of 62 mutations in a cohort of cystic fibrosis patients
RT   from north eastern Italy: their incidence and clinical features of
RT   defined genotypes.";
RL   Hum. Mutat. 2:389-394(1993).
RN   [70]
RP   VARIANTS CYS-31 AND ILE-1220, AND VARIANTS CF LEU-912; TYR-949;
RP   PRO-1065 AND PRO-1071.
RX   PubMed=7522211; DOI=10.1006/geno.1994.1290;
RA   Ghaneb N., Costes B., Girodon E., Martin J., Fanen P., Goossens M.;
RT   "Identification of eight mutations and three sequence variations in
RT   the cystic fibrosis transmembrane conductance regulator (CFTR) gene.";
RL   Genomics 21:434-436(1994).
RN   [71]
RP   VARIANT CF PRO-346.
RX   PubMed=7513296; DOI=10.1007/BF00202817;
RA   Boteva K., Papageorgiou E., Georgiou C., Angastiniotis M.,
RA   Middleton L.T., Constantinou-Deltas C.D.;
RT   "Novel cystic fibrosis mutation associated with mild disease in
RT   Cypriot patients.";
RL   Hum. Genet. 93:529-532(1994).
RN   [72]
RP   VARIANTS CF TYR-199; SER-619; ARG-1005 AND ARG-1291.
RX   PubMed=7525450; DOI=10.1007/BF00211022;
RA   Doerk T., Mekus F., Schmidt K., Bosshammer J., Fislage R., Heuer T.,
RA   Dziadek V., Neumann T., Kaelin N., Wulbrand U., Wulf B.,
RA   von der Hardt H., Maass G., Tuemmler B.;
RT   "Detection of more than 50 different CFTR mutations in a large group
RT   of German cystic fibrosis patients.";
RL   Hum. Genet. 94:533-542(1994).
RN   [73]
RP   VARIANT CF GLU-1249.
RX   PubMed=7520022; DOI=10.1159/000154223;
RA   Greil I., Wagner K., Rosenkranz W.;
RT   "A new missense mutation G1249E in exon 20 of the cystic fibrosis
RT   transmembrane conductance regulator (CFTR) gene.";
RL   Hum. Hered. 44:238-240(1994).
RN   [74]
RP   VARIANT CF GLU-1397.
RX   PubMed=7524913; DOI=10.1093/hmg/3.6.999;
RA   Petreska L., Koceva S., Gordova-Muratovska A., Nestorov R.,
RA   Efremov G.D.;
RT   "Identification of two new mutations (711 +3A-->G and V1397E) in CF
RT   chromosomes of Albanian and Macedonian origin.";
RL   Hum. Mol. Genet. 3:999-1000(1994).
RN   [75]
RP   VARIANT CF CYS-109.
RX   PubMed=7524909; DOI=10.1093/hmg/3.6.1001;
RA   Schaedel C., Kristoffersson A.-C., Kornfaelt R., Holmberg L.;
RT   "A novel cystic fibrosis mutation, Y109C, in the first transmembrane
RT   domain of CFTR.";
RL   Hum. Mol. Genet. 3:1001-1002(1994).
RN   [76]
RP   VARIANT CF THR-120.
RX   PubMed=7517264; DOI=10.1002/humu.1380030308;
RA   Chillon M., Casals T., Gimenez J., Nunes V., Estivill X.;
RT   "Analysis of the CFTR gene in the Spanish population: SSCP-screening
RT   for 60 known mutations and identification of four new mutations (Q30X,
RT   A120T, 1812-1 G-->A, and 3667del4).";
RL   Hum. Mutat. 3:223-230(1994).
RN   [77]
RP   VARIANT CF LEU-87.
RX   PubMed=8081395; DOI=10.1002/humu.1380030412;
RA   Bienvenu T., Petitpretz P., Beldjord C., Kaplan J.C.;
RT   "A missense mutation (F87L) in exon 3 of the cystic fibrosis
RT   transmembrane conductance regulator gene.";
RL   Hum. Mutat. 3:395-396(1994).
RN   [78]
RP   VARIANTS CBAVD ARG-149; LYS-193; GLY-258 AND GLY-800.
RX   PubMed=7529962;
RA   Mercier B., Verlingue C., Lissens W., Silber S.J., Novelli G.,
RA   Bonduelle M., Audrezet M.-P., Ferec C.;
RT   "Is congenital bilateral absence of vas deferens a primary form of
RT   cystic fibrosis? Analyses of the CFTR gene in 67 patients.";
RL   Am. J. Hum. Genet. 56:272-277(1995).
RN   [79]
RP   VARIANTS CBAVD.
RX   PubMed=7539342;
RA   Jezequel P., Dorval I., Fergelot P., Chauvel B., Le Treut A.,
RA   Le Gall J.-Y., Le Lannou D., Blayau M.;
RT   "Structural analysis of CFTR gene in congenital bilateral absence of
RT   vas deferens.";
RL   Clin. Chem. 41:833-835(1995).
RN   [80]
RP   VARIANTS CF GLY-57; LYS-193 AND GLY-579.
RX   PubMed=7544319; DOI=10.1007/BF00210414;
RA   Brancolini V., Cremonesi L., Belloni E., Pappalardo E., Bordoni R.,
RA   Seia M., Russo S., Padoan R., Giunta A., Ferrari M.;
RT   "Search for mutations in pancreatic sufficient cystic fibrosis Italian
RT   patients: detection of 90% of molecular defects and identification of
RT   three novel mutations.";
RL   Hum. Genet. 96:312-318(1995).
RN   [81]
RP   VARIANT CF TRP-206.
RX   PubMed=8522333; DOI=10.1007/BF00210305;
RA   Desgeorges M., Rodier M., Piot M., Demaille J., Claustres M.;
RT   "Four adult patients with the missense mutation L206W and a mild
RT   cystic fibrosis phenotype.";
RL   Hum. Genet. 96:717-720(1995).
RN   [82]
RP   VARIANTS CF LEU-31 AND ARG-1098.
RX   PubMed=7537150; DOI=10.1002/humu.1380050106;
RA   Zielenski J., Markiewicz D., Chen H.S., Schappert K.T., Seller A.,
RA   Durie P., Corey M., Tsui L.-C.;
RT   "Identification of six mutations (R31L, 441delA, 681delC, 1461ins4,
RT   W1089R, E1104X) in the cystic fibrosis transmembrane conductance
RT   regulator (CFTR) gene.";
RL   Hum. Mutat. 5:43-47(1995).
RN   [83]
RP   VARIANT CF ASN-572.
RX   PubMed=7541273; DOI=10.1002/humu.1380050304;
RA   Verlingue C., Kapranov N.I., Mercier B., Ginter E.K., Petrova N.V.,
RA   Audrezet M.P., Ferec C.;
RT   "Complete screening of mutations in the coding sequence of the CFTR
RT   gene in a sample of CF patients from Russia: identification of three
RT   novel alleles.";
RL   Hum. Mutat. 5:205-209(1995).
RN   [84]
RP   VARIANT CF ARG-98.
RX   PubMed=7581407; DOI=10.1002/humu.1380060216;
RA   Romey M.-C., Desgeorges M., Ray P., Godard P., Demaille J.,
RA   Claustres M.;
RT   "Novel missense mutation in the first transmembrane segment of the
RT   CFTR gene (Q98R) identified in a male adult.";
RL   Hum. Mutat. 6:190-191(1995).
RN   [85]
RP   VARIANT CF ILE-338.
RX   PubMed=7543567; DOI=10.1016/S0022-3476(95)70310-1;
RA   Leoni G.B., Pitzalis S., Podda R., Zanda M., Silvetti M., Caocci L.,
RA   Cao A., Rosatelli M.C.;
RT   "A specific cystic fibrosis mutation (T338I) associated with the
RT   phenotype of isolated hypotonic dehydration.";
RL   J. Pediatr. 127:281-283(1995).
RN   [86]
RP   VARIANTS CF PHE-42; LEU-117; ARG-139 AND GLU-1006.
RX   PubMed=7541510; DOI=10.1016/S0890-8508(95)80038-7;
RA   Ferec C., Novelli G., Verlingue C., Quere I., Dallapiccola B.,
RA   Audrezet M.P., Mercier B.;
RT   "Identification of six novel CFTR mutations in a sample of Italian
RT   cystic fibrosis patients.";
RL   Mol. Cell. Probes 9:135-137(1995).
RN   [87]
RP   VARIANT CF SER-665.
RX   PubMed=8800923;
RA   Messaoud T., Verlingue C., Denamur E., Pascaud O., Quere I.,
RA   Fattoum S., Elion J., Ferec C.;
RT   "Distribution of CFTR mutations in cystic fibrosis patients of
RT   Tunisian origin: identification of two novel mutations.";
RL   Eur. J. Hum. Genet. 4:20-24(1996).
RN   [88]
RP   VARIANT CF ARG-314.
RX   PubMed=8829633;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<151::AID-HUMU10>3.0.CO;2-1;
RA   Nasr S.Z., Strong T.V., Mansoura M.K., Dawson D.C., Collins F.S.;
RT   "Novel missense mutation (G314R) in a cystic fibrosis patient with
RT   hepatic failure.";
RL   Hum. Mutat. 7:151-154(1996).
RN   [89]
RP   VARIANT CF CYS-569.
RX   PubMed=8723693;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<375::AID-HUMU17>3.3.CO;2-K;
RA   Petreska L., Plaseska D., Koseva S., Stavljenic-Rukavina A.,
RA   Efremov G.D.;
RT   "A novel mutation in exon 12 (Y569C) of the CFTR gene identified in a
RT   patient of Croatian origin.";
RL   Hum. Mutat. 7:374-375(1996).
RN   [90]
RP   VARIANT CF ARG-1061.
RX   PubMed=8723695;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<376::AID-HUMU18>3.3.CO;2-E;
RA   Bienvenu T., Chertkoff L., Beldjord C., Segal E., Carniglia L.,
RA   Barreiro C., Kaplan J.-C.;
RT   "Identification of three novel mutations in the cystic fibrosis
RT   transmembrane conductance regulator gene in Argentinian CF patients.";
RL   Hum. Mutat. 7:376-377(1996).
RN   [91]
RP   VARIANT CF LEU-562.
RX   PubMed=8956039;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<340::AID-HUMU7>3.3.CO;2-K;
RA   Hughes D.J., Hill A.J.M., Macek M. Jr., Redmond A.O., Nevin N.C.,
RA   Graham C.A.;
RT   "Mutation characterization of CFTR gene in 206 Northern Irish CF
RT   families: thirty mutations, including two novel, account for
RT   approximately 94% of CF chromosomes.";
RL   Hum. Mutat. 8:340-347(1996).
RN   [92]
RP   CHARACTERIZATION OF VARIANT CF ASP-551, CATALYTIC ACTIVITY, FUNCTION,
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=8910473; DOI=10.1074/jbc.271.45.28463;
RA   Li C., Ramjeesingh M., Wang W., Garami E., Hewryk M., Lee D.,
RA   Rommens J.M., Galley K., Bear C.E.;
RT   "ATPase activity of the cystic fibrosis transmembrane conductance
RT   regulator.";
RL   J. Biol. Chem. 271:28463-28468(1996).
RN   [93]
RP   VARIANT CBAVD TYR-50.
RX   PubMed=9067761;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:2<183::AID-HUMU13>3.0.CO;2-Z;
RA   Zielenski J., Patrizio P., Markiewicz D., Asch R.H., Tsui L.-C.;
RT   "Identification of two mutations (S50Y and 4173delC) in the CFTR gene
RT   from patients with congenital bilateral absence of vas deferens
RT   (CBAVD).";
RL   Hum. Mutat. 9:183-184(1997).
RN   [94]
RP   VARIANT CF MET-1140 DEL.
RX   PubMed=9101301;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<368::AID-HUMU13>3.3.CO;2-F;
RA   Clavel C., Pennaforte F., Pigeon F., Verlingue C., Birembaut P.,
RA   Ferec C.;
RT   "Identification of four novel mutations in the cystic fibrosis
RT   transmembrane conductance regulator gene: E664X, 2113delA, 306delTAGA,
RT   and delta M1140.";
RL   Hum. Mutat. 9:368-369(1997).
RN   [95]
RP   VARIANT CF ASP-141.
RX   PubMed=9222768;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<86::AID-HUMU15>3.0.CO;2-W;
RA   Gouya L., Pascaud O., Munck A., Elion J., Denamur E.;
RT   "Novel mutation (A141D) in exon 4 of the CFTR gene identified in an
RT   Algerian patient.";
RL   Hum. Mutat. 10:86-87(1997).
RN   [96]
RP   VARIANT CF CYS-1066.
RX   PubMed=9375855;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:5<387::AID-HUMU9>3.3.CO;2-V;
RA   Casals T., Pacheco P., Barreto C., Gimenez J., Ramos M.D., Pereira S.,
RA   Pinheiro J.A., Cobos N., Curvelo A., Vazquez C., Rocha H.,
RA   Seculi J.L., Perez E., Dapena J., Carrilho E., Duarte A.,
RA   Palacio A.M., Nunes V., Lavinha J., Estivill X.;
RT   "Missense mutation R1066C in the second transmembrane domain of CFTR
RT   causes a severe cystic fibrosis phenotype: study of 19 heterozygous
RT   and 2 homozygous patients.";
RL   Hum. Mutat. 10:387-392(1997).
RN   [97]
RP   VARIANTS CF GLU-85; HIS-117; TYR-287; GLU-455; ASP-551; PRO-1070 AND
RP   LYS-1303.
RX   PubMed=9401006;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:6<436::AID-HUMU4>3.0.CO;2-B;
RA   Shrimpton A.E., Borowitz D., Swender P.;
RT   "Cystic fibrosis mutation frequencies in upstate New York.";
RL   Hum. Mutat. 10:436-442(1997).
RN   [98]
RP   VARIANT CF PHE-311 DEL.
RX   PubMed=9443874; DOI=10.1086/301681;
RA   Friedman K.J., Leigh M.W., Czarnecki P., Feldman G.L.;
RT   "Cystic fibrosis transmembrane-conductance regulator mutations among
RT   African Americans.";
RL   Am. J. Hum. Genet. 62:195-196(1998).
RN   [99]
RP   CHARACTERIZATION OF VARIANTS CF VAL-1137; MET-1140 DEL AND HIS-1152,
RP   MUTAGENESIS OF MET-1137; ILE-1139 AND ASP-1154, SUBCELLULAR LOCATION,
RP   AND FUNCTION.
RX   PubMed=9804160; DOI=10.1016/S0014-5793(98)01042-4;
RA   Vankeerberghen A., Wei L., Teng H., Jaspers M., Cassiman J.J.,
RA   Nilius B., Cuppens H.;
RT   "Characterization of mutations located in exon 18 of the CFTR gene.";
RL   FEBS Lett. 437:1-4(1998).
RN   [100]
RP   VARIANTS CF LEU-1013 AND ILE-1028.
RX   PubMed=9521595; DOI=10.1007/s004390050683;
RA   Onay T., Topaloglu O., Zielenski J., Gokgoz N., Kayserili H.,
RA   Camcioglu Y., Cokugras H., Akcakaya N., Apak M., Tsui L.-C.,
RA   Kirdar B.;
RT   "Analysis of the CFTR gene in Turkish cystic fibrosis patients:
RT   identification of three novel mutations (3172delAC, P1013L and
RT   M1028I).";
RL   Hum. Genet. 102:224-230(1998).
RN   [101]
RP   VARIANTS CF, AND VARIANTS CYS-31; GLN-75; VAL-506 AND CYS-668.
RX   PubMed=9921909; DOI=10.1007/s004390050897;
RA   Bombieri C., Benetazzo M., Saccomani A., Belpinati F., Gile L.S.,
RA   Luisetti M., Pignatti P.F.;
RT   "Complete mutational screening of the CFTR gene in 120 patients with
RT   pulmonary disease.";
RL   Hum. Genet. 103:718-722(1998).
RN   [102]
RP   CHARACTERIZATION OF VARIANTS CF PHE-601; SER-610; THR-613; GLY-614;
RP   THR-618; SER-619; GLN-620; PRO-620; ARG-628; PRO-633 AND SER-665,
RP   CHARACTERIZATION OF VARIANT OLIGOSPERMIA ASP-622, CHARACTERIZATION OF
RP   VARIANTS CBAVD GLY-792 AND GLY-800, AND CHARACTERIZATION OF VARIANT
RP   THORACIC SARCOIDOSIS LYS-828.
RX   PubMed=9736778; DOI=10.1093/hmg/7.11.1761;
RA   Vankeerberghen A., Wei L., Jaspers M., Cassiman J.-J., Nilius B.,
RA   Cuppens H.;
RT   "Characterization of 19 disease-associated missense mutations in the
RT   regulatory domain of the cystic fibrosis transmembrane conductance
RT   regulator.";
RL   Hum. Mol. Genet. 7:1761-1769(1998).
RN   [103]
RP   VARIANTS CF SER-560 AND ASP-569.
RX   PubMed=9482579;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:2<152::AID-HUMU8>3.0.CO;2-L;
RA   Malone G., Haworth A., Schwarz M.J., Cuppens H., Super M.;
RT   "Detection of five novel mutations of the cystic fibrosis
RT   transmembrane regulator (CFTR) gene in Pakistani patients with cystic
RT   fibrosis: Y569D, Q98X, 296+12(T>C), 1161delC and 621+2(T>C).";
RL   Hum. Mutat. 11:152-157(1998).
RN   [104]
RP   VARIANTS CF PHE-13 AND ILE-338.
RX   PubMed=9554753;
RA   Leoni G.B., Pitzalis S., Tonelli R., Cao A.;
RT   "Identification of a novel mutation (S13F) in the CFTR gene in a CF
RT   patient of Sardinian origin.";
RL   Hum. Mutat. 11:337-337(1998).
RN   [105]
RP   VARIANTS CF PRO-117 AND ASP-192 DEL.
RX   PubMed=9452048;
RA   Feldmann D., Sardet A., Cougoureux E., Plouvier E., Fontaine J.-L.,
RA   Tournier G., Aymard P.;
RT   "Identification of three novel mutations in the CFTR gene, R117P,
RT   deltaD192, and 3121+1G-->A in four French patients.";
RL   Hum. Mutat. Suppl. 1:S78-S80(1998).
RN   [106]
RP   VARIANT CF ARG-1065.
RX   PubMed=9452054;
RA   Casals T., Ramos M.D., Gimenez J., Nadal M., Nunes V., Estivill X.;
RT   "Paternal origin of a de novo novel CFTR mutation (L1065R) causing
RT   cystic fibrosis.";
RL   Hum. Mutat. Suppl. 1:S99-S102(1998).
RN   [107]
RP   VARIANT CF ASN-LYS-370 INS.
RX   PubMed=9452073;
RA   Shackleton S., Harris A.;
RT   "A 2-amino acid insertion mutation (1243insACAAAA) in exon 7 of the
RT   CFTR gene.";
RL   Hum. Mutat. Suppl. 1:S156-S157(1998).
RN   [108]
RP   VARIANT CBAVD GLY-513, AND VARIANT MET-470.
RX   PubMed=10651488;
RA   Bienvenu T., Bousquet S., Vidaud D., Hubert D., Francoual C.,
RA   Beldjord C., Kaplan J.-C.;
RT   "A novel missense mutation D513G in exon 10 of the cystic fibrosis
RT   transmembrane conductance regulator (CFTR) gene identified in a French
RT   CBAVD patient.";
RL   Hum. Mutat. 12:213-214(1998).
RN   [109]
RP   VARIANTS CBAVD LEU-111; LYS-244; VAL-544 AND VAL-1364.
RA   de Meeus A., Guittard C., Desgeorges M., Carles S., Demaille J.,
RA   Claustres M.;
RT   "Genetic findings in congenital bilateral aplasia of vas deferens
RT   patients and identification of six novel mutations.";
RL   Hum. Mutat. 12:480-480(1998).
RN   [110]
RP   VARIANT CF GLY-579.
RX   PubMed=10094564;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<173::AID-HUMU20>3.0.CO;2-3;
RA   Picci L., Cameran M., Olante P., Zacchello F., Scarpa M.;
RT   "Identification of a D579G homozygote cystic fibrosis patient with
RT   pancreatic sufficiency and minor lung involvement.";
RL   Hum. Mutat. 13:173-173(1999).
RN   [111]
RP   CHARACTERIZATION OF VARIANT CF TYR-287 AND PHE-508 DEL, SUBCELLULAR
RP   LOCATION, FUNCTION, AND GLYCOSYLATION.
RX   PubMed=12529365; DOI=10.1074/jbc.M212843200;
RA   Silvis M.R., Picciano J.A., Bertrand C., Weixel K., Bridges R.J.,
RA   Bradbury N.A.;
RT   "A mutation in the cystic fibrosis transmembrane conductance regulator
RT   generates a novel internalization sequence and enhances endocytic
RT   rates.";
RL   J. Biol. Chem. 278:11554-11560(2003).
RN   [112]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL, SUBCELLULAR LOCATION,
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15716351; DOI=10.1091/mbc.E04-11-1010;
RA   Kreda S.M., Mall M., Mengos A., Rochelle L., Yankaskas J.,
RA   Riordan J.R., Boucher R.C.;
RT   "Characterization of wild-type and deltaF508 cystic fibrosis
RT   transmembrane regulator in human respiratory epithelia.";
RL   Mol. Biol. Cell 16:2154-2167(2005).
RN   [113]
RP   CHARACTERIZATION OF CF VARIANT LYS-1303, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17182731; DOI=10.1152/ajpcell.00064.2006;
RA   Suaud L., Yan W., Carattino M.D., Robay A., Kleyman T.R.,
RA   Rubenstein R.C.;
RT   "Regulatory interactions of N1303K-CFTR and ENaC in Xenopus oocytes:
RT   evidence that chloride transport is not necessary for inhibition of
RT   ENaC.";
RL   Am. J. Physiol. 292:C1553-C1561(2007).
RN   [114]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-470.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [115]
RP   CHARACTERIZATION OF VARIANT CF HIS-117, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=26846474; DOI=10.1113/JP271723;
RA   Yu Y.C., Sohma Y., Hwang T.C.;
RT   "On the mechanism of gating defects caused by the R117H mutation in
RT   cystic fibrosis transmembrane conductance regulator.";
RL   J. Physiol. (Lond.) 594:3227-3244(2016).
RN   [116]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ILE-539.
RX   PubMed=28001373; DOI=10.1021/acs.biochem.6b00853;
RA   Zhang Z., Baksh M.M., Finn M.G., Heidary D.K., Richards C.I.;
RT   "Direct measurement of trafficking of the cystic fibrosis
RT   transmembrane conductance regulator to the cell surface and binding to
RT   a chemical chaperone.";
RL   Biochemistry 56:240-249(2017).
RN   [117]
RP   CHARACTERIZATION OF VARIANTS CF PHE-508 DEL AND ASP-551, SUBCELLULAR
RP   LOCATION, AND FUNCTION.
RX   PubMed=28087700; DOI=10.1074/jbc.M116.751537;
RA   Meng X., Wang Y., Wang X., Wrennall J.A., Rimington T.L., Li H.,
RA   Cai Z., Ford R.C., Sheppard D.N.;
RT   "Two small molecules restore stability to a sub-population of the
RT   cystic fibrosis transmembrane conductance regulator with the
RT   predominant disease-causing mutation.";
RL   J. Biol. Chem. 292:3706-3719(2017).
CC   -!- FUNCTION: Epithelial ion channel that plays an important role in
CC       the regulation of epithelial ion and water transport and fluid
CC       homeostasis (PubMed:26823428). Mediates the transport of chloride
CC       ions across the cell membrane (PubMed:10792060, PubMed:11524016,
CC       PubMed:11707463, PubMed:12519745, PubMed:15010471,
CC       PubMed:12588899, PubMed:17036051, PubMed:19398555,
CC       PubMed:19621064, PubMed:22178883, PubMed:25330774, PubMed:1712898,
CC       PubMed:8910473, PubMed:9804160, PubMed:12529365, PubMed:17182731,
CC       PubMed:26846474, PubMed:28087700). Channel activity is coupled to
CC       ATP hydrolysis (PubMed:8910473). The ion channel is also permeable
CC       to HCO(3-); selectivity depends on the extracellular chloride
CC       concentration (PubMed:15010471, PubMed:19019741). Exerts its
CC       function also by modulating the activity of other ion channels and
CC       transporters (PubMed:12403779, PubMed:22178883, PubMed:22121115,
CC       PubMed:27941075). Plays an important role in airway fluid
CC       homeostasis (PubMed:16645176, PubMed:19621064, PubMed:26823428).
CC       Contributes to the regulation of the pH and the ion content of the
CC       airway surface fluid layer and thereby plays an important role in
CC       defense against pathogens (PubMed:14668433, PubMed:16645176,
CC       PubMed:26823428). Modulates the activity of the epithelial sodium
CC       channel (ENaC) complex, in part by regulating the cell surface
CC       expression of the ENaC complex (PubMed:17434346, PubMed:27941075,
CC       PubMed:17182731). Inhibits the activity of the ENaC channel
CC       containing subunits SCNN1A, SCNN1B and SCNN1G (PubMed:17182731).
CC       Inhibits the activity of the ENaC channel containing subunits
CC       SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel containing
CC       subunits SCNN1A, SCNN1B and SCNN1G (PubMed:27941075). May regulate
CC       bicarbonate secretion and salvage in epithelial cells by
CC       regulating the transporter SLC4A7 (PubMed:12403779). Can inhibit
CC       the chloride channel activity of ANO1 (PubMed:22178883). Plays a
CC       role in the chloride and bicarbonate homeostasis during sperm
CC       epididymal maturation and capacitation (PubMed:19923167,
CC       PubMed:27714810). {ECO:0000269|PubMed:10792060,
CC       ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:11707463,
CC       ECO:0000269|PubMed:12403779, ECO:0000269|PubMed:12519745,
CC       ECO:0000269|PubMed:12529365, ECO:0000269|PubMed:12588899,
CC       ECO:0000269|PubMed:14668433, ECO:0000269|PubMed:15010471,
CC       ECO:0000269|PubMed:16645176, ECO:0000269|PubMed:17036051,
CC       ECO:0000269|PubMed:1712898, ECO:0000269|PubMed:17182731,
CC       ECO:0000269|PubMed:19019741, ECO:0000269|PubMed:19398555,
CC       ECO:0000269|PubMed:19621064, ECO:0000269|PubMed:22178883,
CC       ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:26627831,
CC       ECO:0000269|PubMed:26823428, ECO:0000269|PubMed:26846474,
CC       ECO:0000269|PubMed:27714810, ECO:0000269|PubMed:27941075,
CC       ECO:0000269|PubMed:28087700, ECO:0000269|PubMed:8910473,
CC       ECO:0000269|PubMed:9804160, ECO:0000305|PubMed:19923167}.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O = ADP + phosphate.
CC       {ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:15284228,
CC       ECO:0000269|PubMed:26627831, ECO:0000269|PubMed:8910473}.
CC   -!- SUBUNIT: Monomer; does not require oligomerization for channel
CC       activity (PubMed:11524016). May form oligomers in the membrane
CC       (PubMed:11524016). Interacts with SLC26A3, SLC26A6 and SHANK2 (By
CC       similarity). Interacts with SLC9A3R1 and MYO6 (PubMed:12403779,
CC       PubMed:15247260, PubMed:11304524). Interacts (via C-terminus) with
CC       GOPC (via PDZ domain); this promotes CFTR internalization and
CC       thereby decreases channel activity (PubMed:11707463,
CC       PubMed:16331976). Interacts with SLC4A7 through SLC9A3R1
CC       (PubMed:12403779). Found in a complex with MYO5B and RAB11A
CC       (PubMed:17462998). Interacts with ANO1 (PubMed:22178883).
CC       Interacts with SLC26A8 (PubMed:22121115). Interacts with AHCYL1;
CC       the interaction increases CFTR activity (By similarity). Interacts
CC       with CSE1L (PubMed:20933420). {ECO:0000250|UniProtKB:P26361,
CC       ECO:0000250|UniProtKB:P34158, ECO:0000269|PubMed:11304524,
CC       ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:11707463,
CC       ECO:0000269|PubMed:12403779, ECO:0000269|PubMed:15247260,
CC       ECO:0000269|PubMed:16331976, ECO:0000269|PubMed:17462998,
CC       ECO:0000269|PubMed:20933420, ECO:0000269|PubMed:22121115,
CC       ECO:0000269|PubMed:22178883}.
CC   -!- INTERACTION:
CC       P51572:BCAP31; NbExp=3; IntAct=EBI-349854, EBI-77683;
CC       P27824:CANX; NbExp=3; IntAct=EBI-349854, EBI-355947;
CC       Q9BUN8:DERL1; NbExp=2; IntAct=EBI-349854, EBI-398977;
CC       Q9H8Y8:GORASP2; NbExp=3; IntAct=EBI-349854, EBI-739467;
CC       P19120:HSPA8 (xeno); NbExp=2; IntAct=EBI-349854, EBI-907802;
CC       O15554:KCNN4; NbExp=5; IntAct=EBI-349854, EBI-2924473;
CC       P05787:KRT8; NbExp=7; IntAct=EBI-349854, EBI-297852;
CC       Q9HBW0:LPAR2; NbExp=4; IntAct=EBI-349854, EBI-765995;
CC       Q5T2W1:PDZK1; NbExp=2; IntAct=EBI-349854, EBI-349819;
CC       Q99942:RNF5; NbExp=3; IntAct=EBI-349854, EBI-348482;
CC       Q9QX74:Shank2 (xeno); NbExp=2; IntAct=EBI-349854, EBI-397902;
CC       Q96RN1:SLC26A8; NbExp=2; IntAct=EBI-349854, EBI-1792052;
CC       O14745:SLC9A3R1; NbExp=5; IntAct=EBI-349854, EBI-349787;
CC       Q15599:SLC9A3R2; NbExp=7; IntAct=EBI-349854, EBI-1149760;
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:12529365,
CC       ECO:0000269|PubMed:1284548, ECO:0000269|PubMed:15247260,
CC       ECO:0000269|PubMed:15716351, ECO:0000269|PubMed:17462998,
CC       ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:19621064,
CC       ECO:0000269|PubMed:20008117, ECO:0000269|PubMed:22207244}; Multi-
CC       pass membrane protein {ECO:0000269|Ref.53}. Early endosome
CC       membrane {ECO:0000269|PubMed:19398555,
CC       ECO:0000269|PubMed:20008117}; Multi-pass membrane protein
CC       {ECO:0000269|Ref.53}. Cell membrane {ECO:0000269|PubMed:10792060,
CC       ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:11707463,
CC       ECO:0000269|PubMed:12588899, ECO:0000269|PubMed:15010471,
CC       ECO:0000269|PubMed:17036051, ECO:0000269|PubMed:1712898,
CC       ECO:0000269|PubMed:17182731, ECO:0000269|PubMed:19019741,
CC       ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:22178883,
CC       ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:26846474,
CC       ECO:0000269|PubMed:28001373, ECO:0000269|PubMed:28087700,
CC       ECO:0000269|PubMed:9804160, ECO:0000305|PubMed:8910473}; Multi-
CC       pass membrane protein {ECO:0000269|Ref.53}. Recycling endosome
CC       membrane {ECO:0000305|PubMed:17462998}; Multi-pass membrane
CC       protein {ECO:0000269|Ref.53}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11707463, ECO:0000269|PubMed:25330774}; Multi-
CC       pass membrane protein {ECO:0000269|Ref.53}. Note=The channel is
CC       internalized from the cell surface into an endosomal recycling
CC       compartment, from where it is recycled to the cell membrane
CC       (PubMed:17462998, PubMed:19398555, PubMed:20008117, Ref.?). In the
CC       oviduct and bronchus, detected on the apical side of epithelial
CC       cells, but not associated with cilia (PubMed:22207244).
CC       {ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:20008117,
CC       ECO:0000269|PubMed:22207244, ECO:0000305|PubMed:17462998}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P13569-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P13569-2; Sequence=VSP_022123;
CC         Note=Exon skipping favored by a high number of TG repeats and a
CC         low number of T repeats at the intron-exon boundary. Causes
CC         congenital bilateral absence of the vas deferens (CBAVD).;
CC       Name=3;
CC         IsoId=P13569-3; Sequence=VSP_022124, VSP_022125;
CC         Note=Alternative acceptor site favored by mutation in an exonic
CC         splicing enhancer (ESE). Causes cystic fibrosis (CF).;
CC   -!- TISSUE SPECIFICITY: Expressed in the respiratory airway, including
CC       bronchial epithelium, and in the female reproductive tract,
CC       including oviduct (at protein level) (PubMed:22207244,
CC       PubMed:15716351). Detected in pancreatic intercalated ducts in the
CC       exocrine tissue, on epithelial cells in intralobular striated
CC       ducts in sublingual salivary glands, on apical membranes of crypt
CC       cells throughout the small and large intestine, and on the
CC       reabsorptive duct in skin sweat glands (PubMed:1284548). Detected
CC       on the equatorial segment of the sperm head (at protein level)
CC       (PubMed:19923167). Detected in nasal and bronchial superficial
CC       epithelium (PubMed:15716351). {ECO:0000269|PubMed:1284548,
CC       ECO:0000269|PubMed:15716351, ECO:0000269|PubMed:19923167,
CC       ECO:0000269|PubMed:22207244}.
CC   -!- DOMAIN: Binds and hydrolyzes ATP via the two cytoplasmic ABC
CC       transporter nucleotide-binding domains (PubMed:15284228). The two
CC       ATP-binding domains interact with each other, forming a head-to-
CC       tail dimer (PubMed:17036051). Normal ATPase activity requires
CC       interaction between the two domains (PubMed:15284228). The first
CC       ABC transporter nucleotide-binding domain has no ATPase activity
CC       by itself (By similarity). {ECO:0000250|UniProtKB:P26361,
CC       ECO:0000269|PubMed:15284228, ECO:0000269|PubMed:17036051}.
CC   -!- DOMAIN: The PDZ-binding motif mediates interactions with GOPC and
CC       with the SLC4A7, SLC9A3R1/EBP50 complex.
CC       {ECO:0000269|PubMed:11304524, ECO:0000269|PubMed:11707463,
CC       ECO:0000269|PubMed:16331976}.
CC   -!- DOMAIN: The R region is intrinsically disordered (PubMed:10792060,
CC       PubMed:17660831). It mediates channel activation when it is
CC       phosphorylated, but not in the absence of phosphorylation
CC       (PubMed:10792060). {ECO:0000269|PubMed:10792060,
CC       ECO:0000269|PubMed:17660831}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12529365,
CC       ECO:0000269|PubMed:1699669, ECO:0000269|PubMed:20008117}.
CC   -!- PTM: Phosphorylated; cAMP treatment promotes phosphorylation and
CC       activates the channel (PubMed:12588899, PubMed:17036051,
CC       PubMed:8910473). Dephosphorylation decreases the ATPase activity
CC       (in vitro) (PubMed:8910473). Phosphorylation at PKA sites
CC       activates the channel (PubMed:10792060, PubMed:12519745,
CC       PubMed:12588899, PubMed:25330774). Phosphorylation at PKC sites
CC       enhances the response to phosphorylation by PKA (PubMed:12588899).
CC       Phosphorylated by AMPK; this inhibits channel activity
CC       (PubMed:12519745). {ECO:0000269|PubMed:10792060,
CC       ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:12588899,
CC       ECO:0000269|PubMed:1377674, ECO:0000269|PubMed:17036051,
CC       ECO:0000269|PubMed:22119790, ECO:0000269|PubMed:25330774,
CC       ECO:0000269|PubMed:8910473, ECO:0000269|PubMed:9385646}.
CC   -!- PTM: Ubiquitinated, leading to its degradation in the lysosome
CC       (PubMed:19398555). Deubiquitination by USP10 in early endosomes
CC       enhances its endocytic recycling to the cell membrane
CC       (PubMed:19398555). Ubiquitinated by RNF185 during ER stress
CC       (PubMed:24019521). {ECO:0000269|PubMed:19398555,
CC       ECO:0000269|PubMed:22119790, ECO:0000269|PubMed:24019521}.
CC   -!- DISEASE: Cystic fibrosis (CF) [MIM:219700]: A common generalized
CC       disorder of the exocrine glands which impairs clearance of
CC       secretions in a variety of organs. It is characterized by the
CC       triad of chronic bronchopulmonary disease (with recurrent
CC       respiratory infections), pancreatic insufficiency (which leads to
CC       malabsorption and growth retardation) and elevated sweat
CC       electrolytes. It is the most common genetic disease in Caucasians,
CC       with a prevalence of about 1 in 2'000 live births. Inheritance is
CC       autosomal recessive. {ECO:0000269|PubMed:10094564,
CC       ECO:0000269|PubMed:12529365, ECO:0000269|PubMed:1284466,
CC       ECO:0000269|PubMed:1284468, ECO:0000269|PubMed:1284529,
CC       ECO:0000269|PubMed:1284530, ECO:0000269|PubMed:1284548,
CC       ECO:0000269|PubMed:15528182, ECO:0000269|PubMed:15716351,
CC       ECO:0000269|PubMed:1695717, ECO:0000269|PubMed:1699669,
CC       ECO:0000269|PubMed:1710600, ECO:0000269|PubMed:1712898,
CC       ECO:0000269|PubMed:17182731, ECO:0000269|PubMed:20008117,
CC       ECO:0000269|PubMed:20150177, ECO:0000269|PubMed:2236053,
CC       ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:26846474,
CC       ECO:0000269|PubMed:28001373, ECO:0000269|PubMed:28087700,
CC       ECO:0000269|PubMed:7504969, ECO:0000269|PubMed:7505694,
CC       ECO:0000269|PubMed:7513296, ECO:0000269|PubMed:7517264,
CC       ECO:0000269|PubMed:7520022, ECO:0000269|PubMed:7522211,
CC       ECO:0000269|PubMed:7524909, ECO:0000269|PubMed:7524913,
CC       ECO:0000269|PubMed:7525450, ECO:0000269|PubMed:7537150,
CC       ECO:0000269|PubMed:7541273, ECO:0000269|PubMed:7541510,
CC       ECO:0000269|PubMed:7543567, ECO:0000269|PubMed:7544319,
CC       ECO:0000269|PubMed:7581407, ECO:0000269|PubMed:7680525,
CC       ECO:0000269|PubMed:7683628, ECO:0000269|PubMed:7683954,
CC       ECO:0000269|PubMed:8081395, ECO:0000269|PubMed:8522333,
CC       ECO:0000269|PubMed:8723693, ECO:0000269|PubMed:8723695,
CC       ECO:0000269|PubMed:8800923, ECO:0000269|PubMed:8829633,
CC       ECO:0000269|PubMed:8910473, ECO:0000269|PubMed:8956039,
CC       ECO:0000269|PubMed:9101301, ECO:0000269|PubMed:9222768,
CC       ECO:0000269|PubMed:9375855, ECO:0000269|PubMed:9401006,
CC       ECO:0000269|PubMed:9443874, ECO:0000269|PubMed:9452048,
CC       ECO:0000269|PubMed:9452054, ECO:0000269|PubMed:9452073,
CC       ECO:0000269|PubMed:9482579, ECO:0000269|PubMed:9521595,
CC       ECO:0000269|PubMed:9554753, ECO:0000269|PubMed:9736778,
CC       ECO:0000269|PubMed:9804160, ECO:0000269|PubMed:9921909}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Congenital bilateral absence of the vas deferens (CBAVD)
CC       [MIM:277180]: Important cause of sterility in men and could
CC       represent an incomplete form of cystic fibrosis, as the majority
CC       of men suffering from cystic fibrosis lack the vas deferens.
CC       {ECO:0000269|PubMed:10651488, ECO:0000269|PubMed:7529962,
CC       ECO:0000269|PubMed:7539342, ECO:0000269|PubMed:9067761,
CC       ECO:0000269|PubMed:9736778, ECO:0000269|Ref.109}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. CFTR transporter (TC 3.A.1.202) subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=CFTR; Note=Cystic fibrosis mutation db;
CC       URL="http://www.genet.sickkids.on.ca/app";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CFTR entry;
CC       URL="https://en.wikipedia.org/wiki/Cystic_fibrosis_transmembrane_conductance_regulator";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=P13569";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28668; AAA35680.1; -; mRNA.
DR   EMBL; M55131; AAC13657.1; -; Genomic_DNA.
DR   EMBL; M55106; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55107; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55108; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55110; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55111; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55112; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55113; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55114; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55115; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55116; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55117; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55118; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55119; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55120; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55121; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55122; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55123; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55124; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55125; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55126; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55127; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55128; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55129; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55130; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; DQ354388; ABC79050.1; -; Genomic_DNA.
DR   EMBL; DQ354389; ABC79052.1; -; Genomic_DNA.
DR   EMBL; DQ354390; ABC79054.1; -; Genomic_DNA.
DR   EMBL; DQ354391; ABC79056.1; -; Genomic_DNA.
DR   EMBL; DQ356258; ABC87055.1; -; Genomic_DNA.
DR   EMBL; DQ356259; ABC87057.1; -; Genomic_DNA.
DR   EMBL; DQ356261; ABC87061.1; -; Genomic_DNA.
DR   EMBL; DQ356262; ABC87063.1; -; Genomic_DNA.
DR   EMBL; DQ356263; ABC87065.1; -; Genomic_DNA.
DR   EMBL; DQ356264; ABC87067.1; -; Genomic_DNA.
DR   EMBL; DQ388128; ABD72183.1; -; Genomic_DNA.
DR   EMBL; DQ388129; ABD72185.1; -; Genomic_DNA.
DR   EMBL; DQ388131; ABD72189.1; -; Genomic_DNA.
DR   EMBL; DQ388132; ABD72191.1; -; Genomic_DNA.
DR   EMBL; DQ388133; ABD72193.1; -; Genomic_DNA.
DR   EMBL; DQ388134; ABD72195.1; -; Genomic_DNA.
DR   EMBL; DQ388135; ABD72197.1; -; Genomic_DNA.
DR   EMBL; DQ388138; ABD72203.1; -; Genomic_DNA.
DR   EMBL; DQ388139; ABD72205.1; -; Genomic_DNA.
DR   EMBL; DQ388140; ABD72207.1; -; Genomic_DNA.
DR   EMBL; DQ388141; ABD72209.1; -; Genomic_DNA.
DR   EMBL; DQ388142; ABD72211.1; -; Genomic_DNA.
DR   EMBL; DQ388143; ABD72213.1; -; Genomic_DNA.
DR   EMBL; DQ388145; ABD72217.1; -; Genomic_DNA.
DR   EMBL; AC000061; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC000111; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236947; EAL24353.1; -; Genomic_DNA.
DR   EMBL; M65196; AAA51979.1; -; Genomic_DNA.
DR   EMBL; M65197; AAA51980.1; -; Genomic_DNA.
DR   CCDS; CCDS5773.1; -. [P13569-1]
DR   PIR; A39069; DVHUCF.
DR   RefSeq; NP_000483.3; NM_000492.3. [P13569-1]
DR   UniGene; Hs.489786; -.
DR   UniGene; Hs.621460; -.
DR   UniGene; Hs.661104; -.
DR   PDB; 1NBD; Model; -; A=425-638.
DR   PDB; 1XMI; X-ray; 2.25 A; A/B/C/D/E=389-678.
DR   PDB; 1XMJ; X-ray; 2.30 A; A=389-677.
DR   PDB; 2BBO; X-ray; 2.55 A; A=389-678.
DR   PDB; 2BBS; X-ray; 2.05 A; A/B=389-677.
DR   PDB; 2BBT; X-ray; 2.30 A; A/B=389-678.
DR   PDB; 2LOB; NMR; -; B=1473-1480.
DR   PDB; 2PZE; X-ray; 1.70 A; A/B=387-646.
DR   PDB; 2PZF; X-ray; 2.00 A; A/B=387-646.
DR   PDB; 2PZG; X-ray; 1.80 A; A/B=375-646.
DR   PDB; 3GD7; X-ray; 2.70 A; A/B/C/D=1193-1427.
DR   PDB; 3ISW; X-ray; 2.80 A; C=5-20.
DR   PDB; 4WZ6; X-ray; 2.05 A; A=389-678.
DR   PDB; 5D2D; X-ray; 2.10 A; C=747-774.
DR   PDB; 5D3E; X-ray; 2.75 A; C/G/K=762-801.
DR   PDB; 5UAK; EM; 3.87 A; A=1-1480.
DR   PDBsum; 1NBD; -.
DR   PDBsum; 1XMI; -.
DR   PDBsum; 1XMJ; -.
DR   PDBsum; 2BBO; -.
DR   PDBsum; 2BBS; -.
DR   PDBsum; 2BBT; -.
DR   PDBsum; 2LOB; -.
DR   PDBsum; 2PZE; -.
DR   PDBsum; 2PZF; -.
DR   PDBsum; 2PZG; -.
DR   PDBsum; 3GD7; -.
DR   PDBsum; 3ISW; -.
DR   PDBsum; 4WZ6; -.
DR   PDBsum; 5D2D; -.
DR   PDBsum; 5D3E; -.
DR   PDBsum; 5UAK; -.
DR   DisProt; DP00012; -.
DR   ProteinModelPortal; P13569; -.
DR   SMR; P13569; -.
DR   BioGrid; 107506; 275.
DR   DIP; DIP-32788N; -.
DR   IntAct; P13569; 140.
DR   MINT; MINT-148539; -.
DR   STRING; 9606.ENSP00000003084; -.
DR   BindingDB; P13569; -.
DR   ChEMBL; CHEMBL4051; -.
DR   DrugBank; DB00887; Bumetanide.
DR   DrugBank; DB04941; Crofelemer.
DR   DrugBank; DB01016; Glyburide.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB08820; Ivacaftor.
DR   DrugBank; DB09280; Lumacaftor.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB04522; Phosphonoserine.
DR   GuidetoPHARMACOLOGY; 707; -.
DR   MoonProt; P13569; -.
DR   TCDB; 3.A.1.202.1; the atp-binding cassette (abc) superfamily.
DR   iPTMnet; P13569; -.
DR   PhosphoSitePlus; P13569; -.
DR   SwissPalm; P13569; -.
DR   BioMuta; CFTR; -.
DR   DMDM; 147744553; -.
DR   PaxDb; P13569; -.
DR   PeptideAtlas; P13569; -.
DR   PRIDE; P13569; -.
DR   DNASU; 1080; -.
DR   Ensembl; ENST00000003084; ENSP00000003084; ENSG00000001626. [P13569-1]
DR   GeneID; 1080; -.
DR   KEGG; hsa:1080; -.
DR   UCSC; uc003vjd.4; human. [P13569-1]
DR   CTD; 1080; -.
DR   DisGeNET; 1080; -.
DR   GeneCards; CFTR; -.
DR   GeneReviews; CFTR; -.
DR   HGNC; HGNC:1884; CFTR.
DR   HPA; CAB001951; -.
DR   HPA; HPA021939; -.
DR   MalaCards; CFTR; -.
DR   MIM; 219700; phenotype.
DR   MIM; 277180; phenotype.
DR   MIM; 602421; gene.
DR   neXtProt; NX_P13569; -.
DR   OpenTargets; ENSG00000001626; -.
DR   Orphanet; 48; Congenital bilateral absence of vas deferens.
DR   Orphanet; 586; Cystic fibrosis.
DR   Orphanet; 676; Hereditary chronic pancreatitis.
DR   Orphanet; 60033; Idiopathic bronchiectasis.
DR   Orphanet; 399805; Male infertility with azoospermia or oligozoospermia due to single gene mutation.
DR   PharmGKB; PA109; -.
DR   eggNOG; KOG0054; Eukaryota.
DR   eggNOG; COG1132; LUCA.
DR   GeneTree; ENSGT00860000133687; -.
DR   HOVERGEN; HBG004169; -.
DR   InParanoid; P13569; -.
DR   KO; K05031; -.
DR   OMA; NALRRCF; -.
DR   OrthoDB; EOG091G00K4; -.
DR   PhylomeDB; P13569; -.
DR   TreeFam; TF105200; -.
DR   BioCyc; MetaCyc:HS00075-MONOMER; -.
DR   BRENDA; 3.6.3.49; 2681.
DR   Reactome; R-HSA-382556; ABC-family proteins mediated transport.
DR   Reactome; R-HSA-5627083; RHO GTPases regulate CFTR trafficking.
DR   Reactome; R-HSA-5678895; Defective CFTR causes cystic fibrosis.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SIGNOR; P13569; -.
DR   EvolutionaryTrace; P13569; -.
DR   GenomeRNAi; 1080; -.
DR   PRO; PR:P13569; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000001626; -.
DR   CleanEx; HS_CFTR; -.
DR   ExpressionAtlas; P13569; baseline and differential.
DR   Genevisible; P13569; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0030660; C:Golgi-associated vesicle membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0055037; C:recycling endosome; IDA:UniProtKB.
DR   GO; GO:0055038; C:recycling endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0016887; F:ATPase activity; IDA:UniProtKB.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:GO_Central.
DR   GO; GO:0043225; F:ATPase-coupled anion transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0015106; F:bicarbonate transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0005254; F:chloride channel activity; IDA:UniProtKB.
DR   GO; GO:0019869; F:chloride channel inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0017081; F:chloride channel regulator activity; TAS:Reactome.
DR   GO; GO:0015108; F:chloride transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005260; F:intracellular ATPase-gated chloride channel activity; IMP:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:UniProtKB.
DR   GO; GO:0015701; P:bicarbonate transport; IDA:UniProtKB.
DR   GO; GO:0071320; P:cellular response to cAMP; ISS:UniProtKB.
DR   GO; GO:1904322; P:cellular response to forskolin; IDA:UniProtKB.
DR   GO; GO:1902476; P:chloride transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030301; P:cholesterol transport; IEA:Ensembl.
DR   GO; GO:0051454; P:intracellular pH elevation; ISS:UniProtKB.
DR   GO; GO:0060081; P:membrane hyperpolarization; ISS:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0050891; P:multicellular organismal water homeostasis; IMP:UniProtKB.
DR   GO; GO:1902161; P:positive regulation of cyclic nucleotide-gated ion channel activity; IMP:UniProtKB.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IMP:UniProtKB.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:UniProtKB.
DR   GO; GO:1902943; P:positive regulation of voltage-gated chloride channel activity; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0048240; P:sperm capacitation; ISS:UniProtKB.
DR   GO; GO:0035377; P:transepithelial water transport; IMP:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006904; P:vesicle docking involved in exocytosis; IEA:Ensembl.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR009147; CFTR/ABCC7.
DR   InterPro; IPR025837; CFTR_reg_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR24223:SF273; PTHR24223:SF273; 1.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   Pfam; PF14396; CFTR_R; 1.
DR   PRINTS; PR01851; CYSFIBREGLTR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 2.
DR   TIGRFAMs; TIGR01271; CFTR_protein; 1.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chloride; Chloride channel; Complete proteome; Disease mutation;
KW   Endoplasmic reticulum; Endosome; Glycoprotein; Hydrolase; Ion channel;
KW   Ion transport; Isopeptide bond; Lipoprotein; Membrane;
KW   Nucleotide-binding; Palmitate; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix;
KW   Transport; Ubl conjugation.
FT   CHAIN         1   1480       Cystic fibrosis transmembrane conductance
FT                                regulator.
FT                                /FTId=PRO_0000093419.
FT   TOPO_DOM      1     77       Cytoplasmic. {ECO:0000305}.
FT   TRANSMEM     78     98       Helical; Name=1. {ECO:0000269|Ref.53}.
FT   TOPO_DOM     99    122       Extracellular. {ECO:0000269|Ref.53}.
FT   TRANSMEM    123    146       Helical; Name=2. {ECO:0000269|Ref.53}.
FT   TOPO_DOM    147    195       Cytoplasmic. {ECO:0000269|Ref.53}.
FT   TRANSMEM    196    216       Helical; Name=3. {ECO:0000269|Ref.53}.
FT   TOPO_DOM    217    222       Extracellular. {ECO:0000269|Ref.53}.
FT   TRANSMEM    223    243       Helical; Name=4. {ECO:0000269|Ref.53}.
FT   TOPO_DOM    244    298       Cytoplasmic. {ECO:0000269|Ref.53}.
FT   TRANSMEM    299    319       Helical; Name=5. {ECO:0000269|Ref.53}.
FT   TOPO_DOM    320    339       Extracellular. {ECO:0000269|Ref.53}.
FT   TRANSMEM    340    358       Helical; Name=6. {ECO:0000269|Ref.53}.
FT   TOPO_DOM    359    858       Cytoplasmic. {ECO:0000269|Ref.53}.
FT   TRANSMEM    859    879       Helical; Name=7. {ECO:0000269|Ref.53}.
FT   TOPO_DOM    880    918       Extracellular. {ECO:0000269|Ref.53}.
FT   TRANSMEM    919    939       Discontinuously helical; Name=8.
FT                                {ECO:0000269|Ref.53}.
FT   TOPO_DOM    940    990       Cytoplasmic. {ECO:0000269|Ref.53}.
FT   TRANSMEM    991   1011       Helical; Name=9. {ECO:0000269|Ref.53}.
FT   TOPO_DOM   1012   1013       Extracellular. {ECO:0000269|Ref.53}.
FT   TRANSMEM   1014   1034       Helical; Name=10. {ECO:0000269|Ref.53}.
FT   TOPO_DOM   1035   1095       Cytoplasmic. {ECO:0000269|Ref.53}.
FT   TRANSMEM   1096   1116       Helical; Name=11. {ECO:0000269|Ref.53}.
FT   TOPO_DOM   1117   1130       Extracellular. {ECO:0000269|Ref.53}.
FT   TRANSMEM   1131   1151       Helical; Name=12. {ECO:0000269|Ref.53}.
FT   TOPO_DOM   1152   1480       Cytoplasmic. {ECO:0000269|Ref.53}.
FT   DOMAIN       81    365       ABC transmembrane type-1 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN      423    646       ABC transporter 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   DOMAIN      859   1155       ABC transmembrane type-1 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN     1210   1443       ABC transporter 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND     458    465       ATP 1. {ECO:0000244|PDB:1XMI,
FT                                ECO:0000244|PDB:1XMJ,
FT                                ECO:0000244|PDB:2BBO,
FT                                ECO:0000244|PDB:2BBS,
FT                                ECO:0000244|PDB:2BBT,
FT                                ECO:0000255|PROSITE-ProRule:PRU00434,
FT                                ECO:0000269|PubMed:15528182}.
FT   NP_BIND    1244   1251       ATP 2. {ECO:0000244|PDB:3GD7,
FT                                ECO:0000255|PROSITE-ProRule:PRU00434}.
FT   REGION      654    831       Intrinsically disordered R region.
FT                                {ECO:0000269|PubMed:10792060}.
FT   MOTIF      1478   1480       PDZ-binding.
FT                                {ECO:0000269|PubMed:11707463,
FT                                ECO:0000269|PubMed:16331976}.
FT   BINDING     401    401       ATP 1. {ECO:0000244|PDB:1XMI,
FT                                ECO:0000244|PDB:1XMJ,
FT                                ECO:0000244|PDB:2BBO,
FT                                ECO:0000244|PDB:2BBS,
FT                                ECO:0000244|PDB:2BBT,
FT                                ECO:0000244|PDB:2PZE,
FT                                ECO:0000244|PDB:2PZF,
FT                                ECO:0000244|PDB:2PZG,
FT                                ECO:0000269|PubMed:15528182,
FT                                ECO:0000269|PubMed:20150177}.
FT   BINDING     434    434       ATP 1. {ECO:0000244|PDB:2PZE,
FT                                ECO:0000244|PDB:2PZF,
FT                                ECO:0000244|PDB:2PZG,
FT                                ECO:0000269|PubMed:20150177}.
FT   BINDING     493    493       ATP 1. {ECO:0000244|PDB:1XMI,
FT                                ECO:0000244|PDB:2BBO,
FT                                ECO:0000244|PDB:2BBS,
FT                                ECO:0000269|PubMed:15528182}.
FT   BINDING    1219   1219       ATP 2. {ECO:0000244|PDB:3GD7}.
FT   MOD_RES     549    549       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     660    660       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:1377674,
FT                                ECO:0000269|PubMed:22119790,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES     670    670       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:25330774}.
FT   MOD_RES     686    686       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:1377674,
FT                                ECO:0000269|PubMed:22119790}.
FT   MOD_RES     700    700       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:1377674,
FT                                ECO:0000269|PubMed:22119790,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES     712    712       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:22119790,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES     717    717       Phosphothreonine.
FT                                {ECO:0000269|PubMed:22119790}.
FT   MOD_RES     737    737       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:1377674,
FT                                ECO:0000269|PubMed:22119790,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES     753    753       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES     768    768       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:1377674,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES     790    790       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:1377674}.
FT   MOD_RES     795    795       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:1377674,
FT                                ECO:0000269|PubMed:22119790,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES     813    813       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:1377674,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:9385646}.
FT   MOD_RES    1444   1444       Phosphoserine.
FT                                {ECO:0000269|PubMed:22119790}.
FT   MOD_RES    1456   1456       Phosphoserine.
FT                                {ECO:0000269|PubMed:22119790}.
FT   LIPID       524    524       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:22119790}.
FT   LIPID      1395   1395       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:22119790}.
FT   CARBOHYD    894    894       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7518437,
FT                                ECO:0000305|PubMed:20008117}.
FT   CARBOHYD    900    900       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:7518437,
FT                                ECO:0000305|PubMed:20008117}.
FT   CROSSLNK    688    688       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:22119790}.
FT   VAR_SEQ     404    464       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_022123.
FT   VAR_SEQ     589    605       SCVCKLMANKTRILVTS -> RRRCSCLLDRNKKTIF (in
FT                                isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_022124.
FT   VAR_SEQ     606   1480       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_022125.
FT   VARIANT      13     13       S -> F (in CF; dbSNP:rs397508635).
FT                                {ECO:0000269|PubMed:9554753}.
FT                                /FTId=VAR_000101.
FT   VARIANT      31     31       R -> C (in dbSNP:rs1800073).
FT                                {ECO:0000269|PubMed:7522211,
FT                                ECO:0000269|PubMed:9921909}.
FT                                /FTId=VAR_000102.
FT   VARIANT      31     31       R -> L (in CF; dbSNP:rs149353983).
FT                                {ECO:0000269|PubMed:7537150}.
FT                                /FTId=VAR_000103.
FT   VARIANT      42     42       S -> F (in CF; dbSNP:rs143456784).
FT                                {ECO:0000269|PubMed:7541510}.
FT                                /FTId=VAR_000104.
FT   VARIANT      44     44       D -> G (in CF; dbSNP:rs1800074).
FT                                /FTId=VAR_000105.
FT   VARIANT      44     44       D -> V (in dbSNP:rs1800074).
FT                                /FTId=VAR_000106.
FT   VARIANT      50     50       S -> Y (in CBAVD; dbSNP:rs397508220).
FT                                {ECO:0000269|PubMed:9067761}.
FT                                /FTId=VAR_000107.
FT   VARIANT      57     57       W -> G (in CF; dbSNP:rs397508272).
FT                                {ECO:0000269|PubMed:7544319}.
FT                                /FTId=VAR_000108.
FT   VARIANT      67     67       P -> L (in CF; dbSNP:rs368505753).
FT                                /FTId=VAR_000109.
FT   VARIANT      74     74       R -> W (in CF; dbSNP:rs115545701).
FT                                /FTId=VAR_000110.
FT   VARIANT      75     75       R -> Q (in dbSNP:rs1800076).
FT                                {ECO:0000269|PubMed:9921909}.
FT                                /FTId=VAR_000111.
FT   VARIANT      85     85       G -> E (in CF; dbSNP:rs75961395).
FT                                {ECO:0000269|PubMed:9401006}.
FT                                /FTId=VAR_000112.
FT   VARIANT      87     87       F -> L (in CF; dbSNP:rs397508403).
FT                                {ECO:0000269|PubMed:8081395}.
FT                                /FTId=VAR_000113.
FT   VARIANT      91     91       G -> R (in CF; dbSNP:rs121908750).
FT                                /FTId=VAR_000114.
FT   VARIANT      92     92       E -> K (in CF; dbSNP:rs121908751).
FT                                {ECO:0000269|PubMed:1284529,
FT                                ECO:0000269|PubMed:7683954}.
FT                                /FTId=VAR_000115.
FT   VARIANT      98     98       Q -> R (in CF; dbSNP:rs397508464).
FT                                {ECO:0000269|PubMed:7581407}.
FT                                /FTId=VAR_000116.
FT   VARIANT     105    105       I -> S (in CF).
FT                                /FTId=VAR_000117.
FT   VARIANT     109    109       Y -> C (in CF; dbSNP:rs121909031).
FT                                {ECO:0000269|PubMed:7524909}.
FT                                /FTId=VAR_000118.
FT   VARIANT     110    110       D -> H (in CF; dbSNP:rs113993958).
FT                                /FTId=VAR_000119.
FT   VARIANT     111    111       P -> L (in CBAVD; dbSNP:rs140502196).
FT                                {ECO:0000269|Ref.109}.
FT                                /FTId=VAR_000120.
FT   VARIANT     117    117       R -> C (in CF; dbSNP:rs77834169).
FT                                {ECO:0000269|PubMed:1284529}.
FT                                /FTId=VAR_000121.
FT   VARIANT     117    117       R -> H (in CF and CBAVD; decreases single
FT                                channel conductance; promotes rapid
FT                                return to the closed state of the
FT                                channel; dbSNP:rs78655421).
FT                                {ECO:0000269|PubMed:26846474,
FT                                ECO:0000269|PubMed:9401006}.
FT                                /FTId=VAR_000122.
FT   VARIANT     117    117       R -> L (in CF; dbSNP:rs78655421).
FT                                {ECO:0000269|PubMed:7541510}.
FT                                /FTId=VAR_000123.
FT   VARIANT     117    117       R -> P (in CF; dbSNP:rs78655421).
FT                                {ECO:0000269|PubMed:9452048}.
FT                                /FTId=VAR_000124.
FT   VARIANT     120    120       A -> T (in CF; dbSNP:rs201958172).
FT                                {ECO:0000269|PubMed:7517264}.
FT                                /FTId=VAR_000125.
FT   VARIANT     138    138       L -> P (in dbSNP:rs1800078).
FT                                /FTId=VAR_009895.
FT   VARIANT     139    139       H -> R (in CF; dbSNP:rs76371115).
FT                                {ECO:0000269|PubMed:7541510}.
FT                                /FTId=VAR_000126.
FT   VARIANT     141    141       A -> D (in CF; dbSNP:rs397508700).
FT                                {ECO:0000269|PubMed:9222768}.
FT                                /FTId=VAR_000127.
FT   VARIANT     148    148       I -> T (in CF; dbSNP:rs35516286).
FT                                /FTId=VAR_000128.
FT   VARIANT     149    149       G -> R (in CBAVD; dbSNP:rs397508718).
FT                                {ECO:0000269|PubMed:7529962}.
FT                                /FTId=VAR_000129.
FT   VARIANT     170    170       R -> H (in dbSNP:rs1800079).
FT                                /FTId=VAR_009896.
FT   VARIANT     178    178       G -> R (in CF; dbSNP:rs80282562).
FT                                /FTId=VAR_000130.
FT   VARIANT     182    182       S -> G (in dbSNP:rs1800080).
FT                                /FTId=VAR_009897.
FT   VARIANT     192    192       Missing (in CF).
FT                                {ECO:0000269|PubMed:9452048}.
FT                                /FTId=VAR_000131.
FT   VARIANT     193    193       E -> K (in CBAVD and CF;
FT                                dbSNP:rs397508759).
FT                                {ECO:0000269|PubMed:7529962,
FT                                ECO:0000269|PubMed:7544319}.
FT                                /FTId=VAR_000132.
FT   VARIANT     199    199       H -> Q (in CF; dbSNP:rs397508765).
FT                                /FTId=VAR_000133.
FT   VARIANT     199    199       H -> Y (in CF; dbSNP:rs121908802).
FT                                {ECO:0000269|PubMed:7525450}.
FT                                /FTId=VAR_000134.
FT   VARIANT     205    205       P -> S (in CF; dbSNP:rs121908803).
FT                                {ECO:0000269|PubMed:7505694}.
FT                                /FTId=VAR_000135.
FT   VARIANT     206    206       L -> W (in CF; dbSNP:rs121908752).
FT                                {ECO:0000269|PubMed:8522333}.
FT                                /FTId=VAR_000136.
FT   VARIANT     225    225       C -> R (in CF; dbSNP:rs397508780).
FT                                /FTId=VAR_000137.
FT   VARIANT     244    244       M -> K (in CBAVD; dbSNP:rs397508790).
FT                                {ECO:0000269|Ref.109}.
FT                                /FTId=VAR_000138.
FT   VARIANT     258    258       R -> G (in CBAVD; dbSNP:rs191456345).
FT                                {ECO:0000269|PubMed:7529962}.
FT                                /FTId=VAR_000139.
FT   VARIANT     287    287       N -> Y (in CF; decreased presence at the
FT                                cell membrane due to increased
FT                                internalization from the apical cell
FT                                membrane; no effect on single channel
FT                                gating and conductance;
FT                                dbSNP:rs397508804).
FT                                {ECO:0000269|PubMed:12529365,
FT                                ECO:0000269|PubMed:9401006}.
FT                                /FTId=VAR_000140.
FT   VARIANT     297    297       R -> Q (in CF; dbSNP:rs143486492).
FT                                /FTId=VAR_000141.
FT   VARIANT     301    301       Y -> C (in CF; dbSNP:rs150691494).
FT                                /FTId=VAR_000142.
FT   VARIANT     307    307       S -> N (in CF; dbSNP:rs397508817).
FT                                /FTId=VAR_000143.
FT   VARIANT     311    311       F -> L (in CF; dbSNP:rs121909016).
FT                                /FTId=VAR_000144.
FT   VARIANT     311    311       Missing (in CF).
FT                                {ECO:0000269|PubMed:9443874}.
FT                                /FTId=VAR_000145.
FT   VARIANT     314    314       G -> E (in CF; dbSNP:rs75763344).
FT                                /FTId=VAR_000146.
FT   VARIANT     314    314       G -> R (in CF; dbSNP:rs397508819).
FT                                {ECO:0000269|PubMed:8829633}.
FT                                /FTId=VAR_000147.
FT   VARIANT     322    322       V -> M (in dbSNP:rs1800085).
FT                                /FTId=VAR_009898.
FT   VARIANT     334    334       R -> W (in CF; mild; does not prevent
FT                                maturation of glycans;
FT                                dbSNP:rs121909011).
FT                                {ECO:0000269|PubMed:1699669}.
FT                                /FTId=VAR_000148.
FT   VARIANT     336    336       I -> K (in CF; dbSNP:rs397508139).
FT                                /FTId=VAR_000150.
FT   VARIANT     338    338       T -> I (in CF; mild; isolated hypotonic
FT                                dehydration; dbSNP:rs77409459).
FT                                {ECO:0000269|PubMed:7543567,
FT                                ECO:0000269|PubMed:9554753}.
FT                                /FTId=VAR_000151.
FT   VARIANT     346    346       L -> P (in CF; dominant mutation but mild
FT                                phenotype; dbSNP:rs397508146).
FT                                {ECO:0000269|PubMed:7513296}.
FT                                /FTId=VAR_000152.
FT   VARIANT     347    347       R -> H (in CF; dbSNP:rs77932196).
FT                                /FTId=VAR_000153.
FT   VARIANT     347    347       R -> L (in CF; dbSNP:rs77932196).
FT                                /FTId=VAR_000154.
FT   VARIANT     347    347       R -> P (in CF; MILD; dbSNP:rs77932196).
FT                                /FTId=VAR_000155.
FT   VARIANT     351    351       T -> S (in dbSNP:rs1800086).
FT                                /FTId=VAR_009899.
FT   VARIANT     352    352       R -> Q (in CF; dbSNP:rs121908753).
FT                                /FTId=VAR_000156.
FT   VARIANT     353    353       Q -> H (in dbSNP:rs1800087).
FT                                /FTId=VAR_009900.
FT   VARIANT     359    360       QT -> KK (in CF; dbSNP:rs397508152).
FT                                /FTId=VAR_000158.
FT   VARIANT     359    359       Q -> K (in CF; dbSNP:rs76879328).
FT                                /FTId=VAR_000157.
FT   VARIANT     370    370       K -> KNK (in CF).
FT                                {ECO:0000269|PubMed:9452073}.
FT                                /FTId=VAR_000159.
FT   VARIANT     455    455       A -> E (in CF; dbSNP:rs74551128).
FT                                {ECO:0000269|PubMed:9401006}.
FT                                /FTId=VAR_000160.
FT   VARIANT     456    456       V -> F (in CF; dbSNP:rs397508195).
FT                                /FTId=VAR_000161.
FT   VARIANT     458    458       G -> V (in CF; dbSNP:rs121909009).
FT                                /FTId=VAR_000162.
FT   VARIANT     467    467       L -> F (in dbSNP:rs1800089).
FT                                /FTId=VAR_000163.
FT   VARIANT     470    470       V -> M (in dbSNP:rs213950).
FT                                {ECO:0000269|PubMed:10651488,
FT                                ECO:0000269|PubMed:1710598,
FT                                ECO:0000269|PubMed:18987736,
FT                                ECO:0000269|PubMed:2475911,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_000164.
FT   VARIANT     480    480       G -> C (in CF; dbSNP:rs79282516).
FT                                /FTId=VAR_000165.
FT   VARIANT     492    492       S -> F (in CF; dbSNP:rs121909017).
FT                                /FTId=VAR_000166.
FT   VARIANT     504    504       E -> Q (in CF; dbSNP:rs397508223).
FT                                /FTId=VAR_000167.
FT   VARIANT     506    506       I -> M (in dbSNP:rs1800092).
FT                                /FTId=VAR_009901.
FT   VARIANT     506    506       I -> V (in dbSNP:rs1800091).
FT                                {ECO:0000269|PubMed:9921909}.
FT                                /FTId=VAR_000168.
FT   VARIANT     507    507       I -> V (in dbSNP:rs1800091).
FT                                /FTId=VAR_000169.
FT   VARIANT     507    507       Missing (in CF; impaired maturation of
FT                                glycan chains).
FT                                {ECO:0000269|PubMed:1699669,
FT                                ECO:0000269|PubMed:1710600}.
FT                                /FTId=VAR_000170.
FT   VARIANT     508    508       F -> C (in dbSNP:rs1800093).
FT                                /FTId=VAR_000172.
FT   VARIANT     508    508       Missing (in CF and CBAVD; most common
FT                                mutation; impairs protein folding and
FT                                stability; causes local changes to the
FT                                surface that mediates interactions
FT                                between domains; decreases frequency of
FT                                channel opening in vitro; decreases
FT                                presence at the cell membrane due to
FT                                retention in intracellular compartments;
FT                                impairs recycling to the cell membrane
FT                                after endocytosis).
FT                                {ECO:0000269|PubMed:12529365,
FT                                ECO:0000269|PubMed:1284548,
FT                                ECO:0000269|PubMed:15528182,
FT                                ECO:0000269|PubMed:15716351,
FT                                ECO:0000269|PubMed:1699669,
FT                                ECO:0000269|PubMed:1710600,
FT                                ECO:0000269|PubMed:20008117,
FT                                ECO:0000269|PubMed:20150177,
FT                                ECO:0000269|PubMed:25330774,
FT                                ECO:0000269|PubMed:28001373,
FT                                ECO:0000269|PubMed:28087700}.
FT                                /FTId=VAR_000171.
FT   VARIANT     513    513       D -> G (in CBAVD; dbSNP:rs397508225).
FT                                {ECO:0000269|PubMed:10651488}.
FT                                /FTId=VAR_000173.
FT   VARIANT     520    520       V -> F (in CF; dbSNP:rs77646904).
FT                                {ECO:0000269|PubMed:1284466}.
FT                                /FTId=VAR_000174.
FT   VARIANT     532    532       K -> E (in dbSNP:rs35032490).
FT                                /FTId=VAR_048150.
FT   VARIANT     544    544       G -> V (in CBAVD; dbSNP:rs397508241).
FT                                {ECO:0000269|Ref.109}.
FT                                /FTId=VAR_000175.
FT   VARIANT     549    549       S -> I (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs121908755).
FT                                {ECO:0000269|PubMed:1699669,
FT                                ECO:0000269|PubMed:1712898}.
FT                                /FTId=VAR_000177.
FT   VARIANT     549    549       S -> N (in CF; dbSNP:rs121908755).
FT                                /FTId=VAR_000176.
FT   VARIANT     549    549       S -> R (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs121909005).
FT                                {ECO:0000269|PubMed:1712898}.
FT                                /FTId=VAR_000178.
FT   VARIANT     551    551       G -> D (in CF; decreases frequency of
FT                                channel opening in vitro; decreases
FT                                channel activity and ATPase activity; no
FT                                effect on trafficking to the cell
FT                                membrane; no effect on protein stability;
FT                                dbSNP:rs75527207).
FT                                {ECO:0000269|PubMed:1284548,
FT                                ECO:0000269|PubMed:1712898,
FT                                ECO:0000269|PubMed:28087700,
FT                                ECO:0000269|PubMed:8910473,
FT                                ECO:0000269|PubMed:9401006}.
FT                                /FTId=VAR_000179.
FT   VARIANT     551    551       G -> S (in CF; no effect on maturation of
FT                                glycans; dbSNP:rs121909013).
FT                                {ECO:0000269|PubMed:1699669}.
FT                                /FTId=VAR_000180.
FT   VARIANT     553    553       R -> Q (in CF; dbSNP:rs121909044).
FT                                /FTId=VAR_000181.
FT   VARIANT     558    558       L -> S (in CF; dbSNP:rs193922504).
FT                                /FTId=VAR_000182.
FT   VARIANT     559    559       A -> T (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs75549581).
FT                                {ECO:0000269|PubMed:1712898}.
FT                                /FTId=VAR_000183.
FT   VARIANT     560    560       R -> K (in CF; dbSNP:rs80055610).
FT                                /FTId=VAR_000184.
FT   VARIANT     560    560       R -> S (in CF; dbSNP:rs397508267).
FT                                {ECO:0000269|PubMed:9482579}.
FT                                /FTId=VAR_000185.
FT   VARIANT     560    560       R -> T (in CF; dbSNP:rs80055610).
FT                                /FTId=VAR_000186.
FT   VARIANT     562    562       V -> I (in dbSNP:rs1800097).
FT                                /FTId=VAR_000187.
FT   VARIANT     562    562       V -> L (in CF; dbSNP:rs1800097).
FT                                {ECO:0000269|PubMed:8956039}.
FT                                /FTId=VAR_000188.
FT   VARIANT     563    563       Y -> N (in CF; dbSNP:rs121909006).
FT                                /FTId=VAR_000189.
FT   VARIANT     569    569       Y -> C (in CF; dbSNP:rs397508277).
FT                                {ECO:0000269|PubMed:8723693}.
FT                                /FTId=VAR_000190.
FT   VARIANT     569    569       Y -> D (in CF; dbSNP:rs397508276).
FT                                {ECO:0000269|PubMed:9482579}.
FT                                /FTId=VAR_000191.
FT   VARIANT     569    569       Y -> H (in CF; dbSNP:rs397508276).
FT                                /FTId=VAR_000192.
FT   VARIANT     571    571       L -> S (in CF; dbSNP:rs397508280).
FT                                /FTId=VAR_000193.
FT   VARIANT     572    572       D -> N (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs397508282).
FT                                {ECO:0000269|PubMed:1712898,
FT                                ECO:0000269|PubMed:7541273}.
FT                                /FTId=VAR_000194.
FT   VARIANT     574    574       P -> H (in CF; dbSNP:rs121908758).
FT                                /FTId=VAR_000195.
FT   VARIANT     576    576       G -> A (in dbSNP:rs1800098).
FT                                /FTId=VAR_000196.
FT   VARIANT     579    579       D -> G (in CF; dbSNP:rs397508288).
FT                                {ECO:0000269|PubMed:10094564,
FT                                ECO:0000269|PubMed:7544319}.
FT                                /FTId=VAR_000197.
FT   VARIANT     601    601       I -> F (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs397508306).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000198.
FT   VARIANT     605    605       S -> F (in dbSNP:rs766874).
FT                                /FTId=VAR_048151.
FT   VARIANT     610    610       L -> S (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs397508311).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000199.
FT   VARIANT     613    613       A -> T (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs201978662).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000200.
FT   VARIANT     614    614       D -> G (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs201124247).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000201.
FT   VARIANT     618    618       I -> T (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs139468767).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000202.
FT   VARIANT     619    619       L -> S (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs397508313).
FT                                {ECO:0000269|PubMed:7525450,
FT                                ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000203.
FT   VARIANT     620    620       H -> P (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs397508314).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000204.
FT   VARIANT     620    620       H -> Q (in CF; no effect on glycan
FT                                maturation but strongly increased channel
FT                                activity; dbSNP:rs397508315).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000205.
FT   VARIANT     622    622       G -> D (in oligospermia; no effect on
FT                                glycan maturation but decreased channel
FT                                activity; dbSNP:rs121908759).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000206.
FT   VARIANT     628    628       G -> R (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs397508316).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000207.
FT   VARIANT     633    633       L -> P (in CF; impaired maturation of
FT                                glycan chains; dbSNP:rs397508318).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000208.
FT   VARIANT     648    648       D -> V (in CF; dbSNP:rs121909033).
FT                                /FTId=VAR_000209.
FT   VARIANT     651    651       D -> N (in CF; dbSNP:rs780526529).
FT                                /FTId=VAR_000210.
FT   VARIANT     654    654       S -> G (in dbSNP:rs1800099).
FT                                /FTId=VAR_009902.
FT   VARIANT     665    665       T -> S (in CF; no effect on glycan
FT                                maturation and channel activity).
FT                                {ECO:0000269|PubMed:8800923,
FT                                ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000211.
FT   VARIANT     668    668       R -> C (in dbSNP:rs1800100).
FT                                {ECO:0000269|PubMed:9921909}.
FT                                /FTId=VAR_000212.
FT   VARIANT     693    693       F -> L (in dbSNP:rs1800101).
FT                                /FTId=VAR_000213.
FT   VARIANT     754    754       V -> M (in CF; dbSNP:rs150157202).
FT                                /FTId=VAR_000214.
FT   VARIANT     766    766       R -> M (in CBAVD; dbSNP:rs397508363).
FT                                /FTId=VAR_000215.
FT   VARIANT     792    792       R -> G (in CBAVD; no effect on glycan
FT                                maturation but decreased channel
FT                                activity; dbSNP:rs145449046).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000216.
FT   VARIANT     800    800       A -> G (in CBAVD; no effect on glycan
FT                                maturation but strongly increased channel
FT                                activity; dbSNP:rs397508373).
FT                                {ECO:0000269|PubMed:7529962,
FT                                ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000217.
FT   VARIANT     807    807       I -> M (in CBAVD; dbSNP:rs1800103).
FT                                /FTId=VAR_000218.
FT   VARIANT     822    822       E -> K (in CF; dbSNP:rs397508378).
FT                                /FTId=VAR_000219.
FT   VARIANT     826    826       E -> K (in thoracic sarcoidosis; no
FT                                effect on glycan maturation and channel
FT                                activity; dbSNP:rs397508381).
FT                                {ECO:0000269|PubMed:9736778}.
FT                                /FTId=VAR_000220.
FT   VARIANT     866    866       C -> Y (in CF; dbSNP:rs193922506).
FT                                /FTId=VAR_000221.
FT   VARIANT     903    903       Y -> H (in dbSNP:rs1800106).
FT                                /FTId=VAR_009903.
FT   VARIANT     909    909       S -> I (in dbSNP:rs1800107).
FT                                /FTId=VAR_009904.
FT   VARIANT     912    912       S -> L (in dbSNP:rs121909034).
FT                                {ECO:0000269|PubMed:7522211}.
FT                                /FTId=VAR_000222.
FT   VARIANT     913    913       Y -> C (in CF; dbSNP:rs121909008).
FT                                /FTId=VAR_000223.
FT   VARIANT     917    917       Y -> C (in CF; dbSNP:rs397508428).
FT                                /FTId=VAR_000224.
FT   VARIANT     949    949       H -> Y (in CF; dbSNP:rs121909035).
FT                                {ECO:0000269|PubMed:7522211}.
FT                                /FTId=VAR_000225.
FT   VARIANT     952    952       M -> I (in CF; dbSNP:rs151048781).
FT                                /FTId=VAR_000226.
FT   VARIANT     967    967       L -> S (in dbSNP:rs1800110).
FT                                /FTId=VAR_009905.
FT   VARIANT     997    997       L -> F (in CF; dbSNP:rs1800111).
FT                                /FTId=VAR_000227.
FT   VARIANT    1005   1005       I -> R (in CF; dbSNP:rs397508479).
FT                                {ECO:0000269|PubMed:7525450}.
FT                                /FTId=VAR_000228.
FT   VARIANT    1006   1006       A -> E (in CF; dbSNP:rs397508480).
FT                                {ECO:0000269|PubMed:7541510}.
FT                                /FTId=VAR_000229.
FT   VARIANT    1013   1013       P -> L (in CF; dbSNP:rs193922516).
FT                                {ECO:0000269|PubMed:9521595}.
FT                                /FTId=VAR_000230.
FT   VARIANT    1028   1028       M -> I (in CF; dbSNP:rs200553511).
FT                                {ECO:0000269|PubMed:9521595}.
FT                                /FTId=VAR_000231.
FT   VARIANT    1052   1052       F -> V (in CF; dbSNP:rs150212784).
FT                                {ECO:0000269|PubMed:7683628}.
FT                                /FTId=VAR_000232.
FT   VARIANT    1061   1061       G -> R (in CF; dbSNP:rs142394380).
FT                                {ECO:0000269|PubMed:7683628,
FT                                ECO:0000269|PubMed:8723695}.
FT                                /FTId=VAR_000233.
FT   VARIANT    1065   1065       L -> P (in CF; dbSNP:rs121909036).
FT                                {ECO:0000269|PubMed:7522211}.
FT                                /FTId=VAR_000234.
FT   VARIANT    1065   1065       L -> R (in CF; dbSNP:rs121909036).
FT                                {ECO:0000269|PubMed:9452054}.
FT                                /FTId=VAR_000235.
FT   VARIANT    1066   1066       R -> C (in CF; dbSNP:rs78194216).
FT                                {ECO:0000269|PubMed:9375855}.
FT                                /FTId=VAR_000236.
FT   VARIANT    1066   1066       R -> H (in CF; dbSNP:rs121909019).
FT                                /FTId=VAR_000237.
FT   VARIANT    1066   1066       R -> L (in CF; dbSNP:rs121909019).
FT                                {ECO:0000269|PubMed:7683628}.
FT                                /FTId=VAR_000238.
FT   VARIANT    1067   1067       A -> T (in CF; dbSNP:rs121909020).
FT                                /FTId=VAR_000239.
FT   VARIANT    1067   1067       A -> V (in dbSNP:rs1800114).
FT                                /FTId=VAR_000240.
FT   VARIANT    1070   1070       R -> P (in CF; dbSNP:rs78769542).
FT                                {ECO:0000269|PubMed:9401006}.
FT                                /FTId=VAR_000242.
FT   VARIANT    1070   1070       R -> Q (in CF; dbSNP:rs78769542).
FT                                {ECO:0000269|PubMed:7683628}.
FT                                /FTId=VAR_000241.
FT   VARIANT    1070   1070       R -> W (in CBAVD; dbSNP:rs202179988).
FT                                /FTId=VAR_011564.
FT   VARIANT    1071   1071       Q -> P (in CF; dbSNP:rs121909037).
FT                                {ECO:0000269|PubMed:7522211}.
FT                                /FTId=VAR_000243.
FT   VARIANT    1072   1072       P -> L (in CF).
FT                                /FTId=VAR_000244.
FT   VARIANT    1077   1077       L -> P (in CF; dbSNP:rs139304906).
FT                                /FTId=VAR_000245.
FT   VARIANT    1085   1085       H -> R (in CF; dbSNP:rs79635528).
FT                                {ECO:0000269|PubMed:7683628}.
FT                                /FTId=VAR_000246.
FT   VARIANT    1098   1098       W -> R (in CF; dbSNP:rs397508531).
FT                                {ECO:0000269|PubMed:7537150}.
FT                                /FTId=VAR_000247.
FT   VARIANT    1101   1101       M -> K (in CF; dbSNP:rs36210737).
FT                                {ECO:0000269|PubMed:7680525}.
FT                                /FTId=VAR_000248.
FT   VARIANT    1101   1101       M -> R (in CF; dbSNP:rs36210737).
FT                                {ECO:0000269|PubMed:7683628}.
FT                                /FTId=VAR_011565.
FT   VARIANT    1137   1137       M -> V (in CF; decreases channel
FT                                activity; no visible effect on protein
FT                                maturation; dbSNP:rs397508553).
FT                                {ECO:0000269|PubMed:9804160}.
FT                                /FTId=VAR_000249.
FT   VARIANT    1140   1140       Missing (in CF; abolishes channel
FT                                activity; no visible effect on protein
FT                                maturation). {ECO:0000269|PubMed:9101301,
FT                                ECO:0000269|PubMed:9804160}.
FT                                /FTId=VAR_000250.
FT   VARIANT    1152   1152       D -> H (in CF; decreases channel
FT                                activity; no visible effect on protein
FT                                maturation; dbSNP:rs75541969).
FT                                {ECO:0000269|PubMed:9804160}.
FT                                /FTId=VAR_000251.
FT   VARIANT    1162   1162       R -> L (in dbSNP:rs1800120).
FT                                /FTId=VAR_000252.
FT   VARIANT    1220   1220       T -> I (in dbSNP:rs1800123).
FT                                {ECO:0000269|PubMed:7522211}.
FT                                /FTId=VAR_000253.
FT   VARIANT    1234   1234       I -> V (in CF; dbSNP:rs75389940).
FT                                /FTId=VAR_000254.
FT   VARIANT    1235   1235       S -> R (in CF; dbSNP:rs34911792).
FT                                /FTId=VAR_000255.
FT   VARIANT    1244   1244       G -> E (in CF; dbSNP:rs267606723).
FT                                /FTId=VAR_000256.
FT   VARIANT    1249   1249       G -> E (in CF; dbSNP:rs121909040).
FT                                {ECO:0000269|PubMed:7520022}.
FT                                /FTId=VAR_000257.
FT   VARIANT    1251   1251       S -> N (in CF; dbSNP:rs74503330).
FT                                /FTId=VAR_000258.
FT   VARIANT    1255   1255       S -> P (in CF; dbSNP:rs121909041).
FT                                {ECO:0000269|PubMed:1284530}.
FT                                /FTId=VAR_000259.
FT   VARIANT    1270   1270       D -> N (in CF; dbSNP:rs11971167).
FT                                /FTId=VAR_000260.
FT   VARIANT    1282   1282       W -> R (in CF; dbSNP:rs397508616).
FT                                /FTId=VAR_000261.
FT   VARIANT    1283   1283       R -> M (in CF; dbSNP:rs77902683).
FT                                {ECO:0000269|PubMed:1284468}.
FT                                /FTId=VAR_000262.
FT   VARIANT    1286   1286       F -> S (in CF; dbSNP:rs121909028).
FT                                /FTId=VAR_000263.
FT   VARIANT    1291   1291       Q -> H (in CF; dbSNP:rs121909015).
FT                                {ECO:0000269|PubMed:1284466}.
FT                                /FTId=VAR_000264.
FT   VARIANT    1291   1291       Q -> R (in CF; dbSNP:rs397508621).
FT                                {ECO:0000269|PubMed:7525450}.
FT                                /FTId=VAR_000265.
FT   VARIANT    1303   1303       N -> H (in CF; dbSNP:rs121909042).
FT                                /FTId=VAR_000266.
FT   VARIANT    1303   1303       N -> K (in CF; impaired maturation of
FT                                glycan chains; has low in vitro channel
FT                                activity at low temperature;
FT                                dbSNP:rs80034486).
FT                                {ECO:0000269|PubMed:1712898,
FT                                ECO:0000269|PubMed:17182731,
FT                                ECO:0000269|PubMed:9401006}.
FT                                /FTId=VAR_000267.
FT   VARIANT    1349   1349       G -> D (in CF; no effect on maturation of
FT                                glycan chains; has in vitro channel
FT                                activity; dbSNP:rs193922525).
FT                                {ECO:0000269|PubMed:1712898}.
FT                                /FTId=VAR_000268.
FT   VARIANT    1364   1364       A -> V (in CBAVD; dbSNP:rs397508670).
FT                                {ECO:0000269|Ref.109}.
FT                                /FTId=VAR_000269.
FT   VARIANT    1397   1397       V -> E (in CF; dbSNP:rs397508691).
FT                                {ECO:0000269|PubMed:7524913}.
FT                                /FTId=VAR_000270.
FT   VARIANT    1453   1453       R -> W (in dbSNP:rs4148725).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_048152.
FT   MUTAGEN     464    464       K->M: Impaired maturation of glycan
FT                                chains indicating impaired trafficking
FT                                from the endoplasmic reticulum to the
FT                                cell membrane.
FT                                {ECO:0000269|PubMed:1699669}.
FT   MUTAGEN     508    508       F->R: Impaired maturation of glycan
FT                                chains indicating impaired trafficking
FT                                from the endoplasmic reticulum to the
FT                                cell membrane.
FT                                {ECO:0000269|PubMed:1699669,
FT                                ECO:0000269|PubMed:1712898}.
FT   MUTAGEN     539    539       I->T: Enhances trafficking from the
FT                                endoplasmic reticulum to the cell
FT                                membrane. {ECO:0000269|PubMed:28001373}.
FT   MUTAGEN     894    894       N->D: Abolishes N-glycosylation, enhances
FT                                endocytosis and impairs subsequent
FT                                recycling to the cell surface; when
FT                                associated with D-900.
FT                                {ECO:0000269|PubMed:20008117}.
FT   MUTAGEN     900    900       N->D: Abolishes N-glycosylation, enhances
FT                                endocytosis and impairs subsequent
FT                                recycling to the cell surface; when
FT                                associated with D-894.
FT                                {ECO:0000269|PubMed:20008117}.
FT   MUTAGEN    1137   1137       M->R: Abolishes channel activity. Impairs
FT                                protein maturation, suggesting the
FT                                protein is retained in the endoplasmic
FT                                reticulum. {ECO:0000269|PubMed:9804160}.
FT   MUTAGEN    1139   1139       I->V: Decreases channel activity, no
FT                                visible effect on protein maturation.
FT                                {ECO:0000269|PubMed:9804160}.
FT   MUTAGEN    1154   1154       D->G: Decreases channel activity, no
FT                                visible effect on protein maturation.
FT                                {ECO:0000269|PubMed:9804160}.
FT   MUTAGEN    1250   1250       K->M: No effect on maturation of glycans,
FT                                suggesting that trafficking to the plasma
FT                                membrane is not altered.
FT                                {ECO:0000269|PubMed:1699669}.
FT   CONFLICT    620    620       H -> N (in Ref. 1; AAA35680).
FT                                {ECO:0000305}.
FT   CONFLICT    833    833       F -> L (in Ref. 1; AAA35680).
FT                                {ECO:0000305}.
FT   STRAND       11     19       {ECO:0000244|PDB:3ISW}.
FT   STRAND      390    399       {ECO:0000244|PDB:2PZE}.
FT   HELIX       403    411       {ECO:0000244|PDB:2BBS}.
FT   HELIX       414    417       {ECO:0000244|PDB:2BBT}.
FT   HELIX       433    436       {ECO:0000244|PDB:1XMI}.
FT   STRAND      440    449       {ECO:0000244|PDB:2PZE}.
FT   STRAND      453    457       {ECO:0000244|PDB:2PZE}.
FT   HELIX       464    471       {ECO:0000244|PDB:2PZE}.
FT   STRAND      478    484       {ECO:0000244|PDB:2PZE}.
FT   STRAND      488    491       {ECO:0000244|PDB:2PZE}.
FT   STRAND      499    501       {ECO:0000244|PDB:2PZG}.
FT   HELIX       502    507       {ECO:0000244|PDB:2PZE}.
FT   HELIX       514    523       {ECO:0000244|PDB:2PZE}.
FT   HELIX       527    530       {ECO:0000244|PDB:2PZE}.
FT   STRAND      533    535       {ECO:0000244|PDB:2PZF}.
FT   HELIX       536    538       {ECO:0000244|PDB:2PZE}.
FT   STRAND      540    542       {ECO:0000244|PDB:1XMJ}.
FT   HELIX       550    563       {ECO:0000244|PDB:2PZE}.
FT   STRAND      567    573       {ECO:0000244|PDB:2PZE}.
FT   TURN        574    577       {ECO:0000244|PDB:2PZE}.
FT   HELIX       580    589       {ECO:0000244|PDB:2PZE}.
FT   HELIX       590    594       {ECO:0000244|PDB:2PZE}.
FT   TURN        595    597       {ECO:0000244|PDB:2PZE}.
FT   STRAND      598    603       {ECO:0000244|PDB:2PZE}.
FT   HELIX       607    612       {ECO:0000244|PDB:2PZE}.
FT   STRAND      614    620       {ECO:0000244|PDB:2PZE}.
FT   STRAND      623    628       {ECO:0000244|PDB:2PZE}.
FT   HELIX       630    634       {ECO:0000244|PDB:2PZE}.
FT   HELIX       640    644       {ECO:0000244|PDB:2PZE}.
FT   HELIX       650    652       {ECO:0000244|PDB:2BBS}.
FT   HELIX       655    669       {ECO:0000244|PDB:2BBS}.
FT   STRAND     1204   1207       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1210   1223       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1226   1234       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1239   1245       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1250   1258       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1261   1271       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1279   1284       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1286   1290       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1297   1299       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1300   1304       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1312   1321       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1325   1328       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1334   1336       {ECO:0000244|PDB:3GD7}.
FT   TURN       1341   1345       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1348   1361       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1366   1371       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1372   1375       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1378   1389       {ECO:0000244|PDB:3GD7}.
FT   TURN       1390   1394       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1397   1400       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1402   1404       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1405   1407       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1411   1417       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1420   1426       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1427   1432       {ECO:0000244|PDB:3GD7}.
FT   HELIX      1436   1441       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1442   1445       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1448   1457       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1462   1465       {ECO:0000244|PDB:3GD7}.
FT   STRAND     1478   1480       {ECO:0000244|PDB:2LOB}.
SQ   SEQUENCE   1480 AA;  168142 MW;  8D082AA2E768C065 CRC64;
     MQRSPLEKAS VVSKLFFSWT RPILRKGYRQ RLELSDIYQI PSVDSADNLS EKLEREWDRE
     LASKKNPKLI NALRRCFFWR FMFYGIFLYL GEVTKAVQPL LLGRIIASYD PDNKEERSIA
     IYLGIGLCLL FIVRTLLLHP AIFGLHHIGM QMRIAMFSLI YKKTLKLSSR VLDKISIGQL
     VSLLSNNLNK FDEGLALAHF VWIAPLQVAL LMGLIWELLQ ASAFCGLGFL IVLALFQAGL
     GRMMMKYRDQ RAGKISERLV ITSEMIENIQ SVKAYCWEEA MEKMIENLRQ TELKLTRKAA
     YVRYFNSSAF FFSGFFVVFL SVLPYALIKG IILRKIFTTI SFCIVLRMAV TRQFPWAVQT
     WYDSLGAINK IQDFLQKQEY KTLEYNLTTT EVVMENVTAF WEEGFGELFE KAKQNNNNRK
     TSNGDDSLFF SNFSLLGTPV LKDINFKIER GQLLAVAGST GAGKTSLLMV IMGELEPSEG
     KIKHSGRISF CSQFSWIMPG TIKENIIFGV SYDEYRYRSV IKACQLEEDI SKFAEKDNIV
     LGEGGITLSG GQRARISLAR AVYKDADLYL LDSPFGYLDV LTEKEIFESC VCKLMANKTR
     ILVTSKMEHL KKADKILILH EGSSYFYGTF SELQNLQPDF SSKLMGCDSF DQFSAERRNS
     ILTETLHRFS LEGDAPVSWT ETKKQSFKQT GEFGEKRKNS ILNPINSIRK FSIVQKTPLQ
     MNGIEEDSDE PLERRLSLVP DSEQGEAILP RISVISTGPT LQARRRQSVL NLMTHSVNQG
     QNIHRKTTAS TRKVSLAPQA NLTELDIYSR RLSQETGLEI SEEINEEDLK ECFFDDMESI
     PAVTTWNTYL RYITVHKSLI FVLIWCLVIF LAEVAASLVV LWLLGNTPLQ DKGNSTHSRN
     NSYAVIITST SSYYVFYIYV GVADTLLAMG FFRGLPLVHT LITVSKILHH KMLHSVLQAP
     MSTLNTLKAG GILNRFSKDI AILDDLLPLT IFDFIQLLLI VIGAIAVVAV LQPYIFVATV
     PVIVAFIMLR AYFLQTSQQL KQLESEGRSP IFTHLVTSLK GLWTLRAFGR QPYFETLFHK
     ALNLHTANWF LYLSTLRWFQ MRIEMIFVIF FIAVTFISIL TTGEGEGRVG IILTLAMNIM
     STLQWAVNSS IDVDSLMRSV SRVFKFIDMP TEGKPTKSTK PYKNGQLSKV MIIENSHVKK
     DDIWPSGGQM TVKDLTAKYT EGGNAILENI SFSISPGQRV GLLGRTGSGK STLLSAFLRL
     LNTEGEIQID GVSWDSITLQ QWRKAFGVIP QKVFIFSGTF RKNLDPYEQW SDQEIWKVAD
     EVGLRSVIEQ FPGKLDFVLV DGGCVLSHGH KQLMCLARSV LSKAKILLLD EPSAHLDPVT
     YQIIRRTLKQ AFADCTVILC EHRIEAMLEC QQFLVIEENK VRQYDSIQKL LNERSLFRQA
     ISPSDRVKLF PHRNSSKCKS KPQIAALKEE TEEEVQDTRL
//
